



# PASPCR

## Newsletter

Volume 5 Number 2

June, 1997

### Introduction . . .

by the Publications Committee

The *PASPCR Newsletter* is published quarterly and is intended to serve as a means of communication for the members of our Society. As such, we invite our membership to actively contribute to the *PASPCR Newsletter*; help us to update the Job Listings, Calendar of Events, Meeting Reports, Abstracts in press and other items of general membership interest. If you attend a scientific meeting at which you heard about work which you think will be of interest to the membership of the **PASPCR**, please write a few paragraphs summarizing what was presented and share it with us. If you should have a change of affiliation or address, we'd like to know that, too. This is **your** *Newsletter*, and we depend upon you to help us make sure it best serves the Society's needs. Contributions and comments can be sent to any of the members of the Publications Committee.

**NEW!** WorldWideWeb Pages for the PASPCR. The PASPCR now has its own **WWW** home page. We plan this to be a major source of current information for the PASPCR membership. The address for the page is: <http://lenti.med.umn.edu/paspcr>. This site contains information on the goals of the society, future meetings, council information, past issues of the *PASPCR Newsletter* as well as links to other sites including the InterPig DataBase, the International Pigment Cell Conference in Nagoya and the International Federation of Pigment Cell Societies (IFPCS).

We have now included the membership directory on that page; please notify us if you wish any or all of your information to be deleted or modified on that site.

The PASPCR WWW page system is still under construction and we want to know if there is any other information you would like located on this site.

Please check out the PASPCR web site and send any comments and/or suggestions to either the PASPCR WebMaster Bill Oetting at [bill@lenti.med.umn.edu](mailto:bill@lenti.med.umn.edu) or to Vince Hearing at [hearingv@nih.gov](mailto:hearingv@nih.gov).

### IN THIS ISSUE . . . . .

Introduction	p 1
PASPCR Contact Information	p 2
Calendar of Events	p 2
Welcome to New Members	p 3
Corporate Sponsors	p 3
VII <sup>th</sup> PASPCR Meeting Program	p 3
<i>Pigment Cell Research</i> Wants YOU	p 9
XVII <sup>th</sup> International Pigment Cell Conf	p 10
Positions Wanted / Available	p 11
INTERPIG DataBase	p 11
Bibliography	p 12
Demographics of the PASPCR	p 23

**PanAmerican Society for  
Pigment Cell Research**

c/o **Dr. James J. Nordlund**  
Department of Dermatology  
University of Cincinnati  
231 Bethesda Avenue  
Cincinnati, OH 45267-0592  
FAX: (513) 558-0198

**Officers**

Sally Frost-Mason  
*President*  
Richard A. King  
*President-Elect*  
James J. Nordlund  
*Secretary/Treasurer*

**Council Members**

Gregory S. Barsh  
Alan N. Houghton  
M. Lynn Lamoreux  
Kenneth A. Mason  
Frank L. Meyskens, Jr.  
David A. Norris  
William S. Oetting  
John M. Pawelek  
Walter C. Quevedo, Jr.

**IFPCS Representative**

Vincent J. Hearing  
*Past-President*

The **PASPCR Newsletter** is published quarterly; for further information and/or to submit articles, contact the:

**Publications Committee:**

**Dr. Kenneth A. Mason (chair)**

University of Kansas  
Department of Biochemistry  
Lawrence, KS 66045  
Phone: 913/864-4279  
FAX: 913/864-5321

**Frank L. Meyskens, Jr.**

University of California - Cancer Center  
101 City Drive  
Orange, CA 92668  
Phone: 714/456-6310  
FAX: 714/456-5039

**David A. Norris**

Department of Dermatology  
University of Colorado Medical Center  
4200 East 9<sup>th</sup> Avenue  
Denver, CO 80262  
Phone: 303/372-1142  
FAX: 303/372-1159

**Calendar of Events :**

**Jun 10 - 14, 1997** 4<sup>th</sup> World Conference on Melanoma to be held in Sydney, Australia (contact: The Melanoma Foundation, PO Box M123, Camperdown, NSW 2050 Australia; FAX: +61 2/550-6316)

**Jun 15- 18, 1997** VII<sup>th</sup> PASPCR Annual Meeting, to be held in Providence, RI (contact: Dr. Walter C Quevedo, Jr., Brown University, Division of Biology and Medicine, Providence, RI 02912; FAX: 401/863-1971)

**Jun 22 - 24, 1997** International Meeting "Pigmentary Disorders from a Global Perspectives" to be held in Bali, Indonesia (contact: Bureau PAOG, Tafelbergweg 25, 1105 BC Amsterdam, The Netherlands; FAX: +31 20/696-3229)

**Aug 24 - 29, 1997** International Congress of Biochem & Mol Biology with the Amer Soc for Biochem & Mol Biology, to be held in San Francisco, CA (contact: FASEB, 9650 Rockville Pike, Bethesda, MD 20814, USA; FAX: +1 301/530-7014)

**Oct 9- 11, 1997** 7<sup>th</sup> ESPCR Annual Meeting, to be held in Bordeaux, France (contact: 7<sup>th</sup> ESPCR Meeting Bordeaux, c/o Congres Seminaires Organisation, 81, Boulevard, Pierre 1<sup>er</sup>, 33110 Le Bouscat, Bordeaux, France)

**Dec 13 - 17, 1997** American Society for Cell Biology Annual Meeting, to be held in Washington DC (contact: FASEB, 9650 Rockville Pike, Bethesda, MD 20814, USA; FAX: +1 301/530-7014)

**Oct 15 - 18, 1998** VIII<sup>th</sup> PASPCR Annual Meeting, to be held in Snowmass, CO (contact: Dr. David Norris, Dermatology Dept, Univ of Colorado Medical Center, Denver, CO 80262 USA; FAX: +1 303/372-1159)

**Oct 30 - Nov 3, 1999** XVII<sup>th</sup> International Pigment Cell Conference, to be held in Nagoya, Japan (contact: Dr. Shosuke Ito, Fujita Health University School of Health Sciences, Toyoake, Aichi 470-11, Japan; Phone: +81-562-93-2595; Fax: +81-562-93-4595; Email: sito@fujita-hu.ac.jp)

---

## Welcome to New Members

by James J Nordlund

We welcome the following new member to the PASPCR . . .

James L. Christiansen	Donald B Galbraith	Thomas J Hornyak
Eric Jacobson	Eun-Jung Jim	Shinobu Kato
Jaskiran Kaur	Rivka Rachel	Seonghyang Sohn
Anjaiah Srirangam	Antonis Zeruos	Hua (Kelly) Zhang

If anyone is interested in joining our Society or wishes to sponsor a member, application forms can be obtained from Dr. James J. Nordlund at the PASPCR Secretary/Treasurer's office.

---

## Corporate Sponsors

by James J Nordlund

The PASPCR would like to acknowledge and thank our Corporate Sponsors; the list below reflects contributions over the past 2 years. Financial gifts from these sponsors have allowed our Society to increase benefits to the membership far out of proportion to the actual dues collected from members. Monies contributed by these sponsors have been used over the years to support various PASPCR functions including our Young Investigator Award program, meeting travel stipends, annual meeting expenses and this Newsletter.

### *GOLD Corporate Patrons*

ICN Pharmaceuticals, Inc  
Lawrence M Gelb Research  
Foundation of Clairol, Inc  
Ortho Pharmaceutical Corp

### *SILVER Corporate Patrons*

Avon Products, Inc  
Chesebrough-Pond's USA Co  
Procter and Gamble Co  
Shiseido Co, Ltd

### *Corporate Patrons*

Galderma Laboratories, Inc  
Stiefel Laboratories

---

## VII<sup>th</sup> Annual Meeting of the PASPCR

by Walter Quevedo / Hal Swartz

June 15<sup>th</sup> - 18<sup>th</sup>, 1997    The Westin Hotel    Providence, RI

The Organizing Committee for the 7<sup>th</sup> Meeting of the PanAmerican Society for Pigment Cell Research enthusiastically invites you to attend the Society's annual meeting this June 15<sup>th</sup> - 18<sup>th</sup> in Providence. The Westin Hotel is attractive to the eye and brought to life by a staff that is friendly, professional and efficient. Alistair Cooke has said that Spring in New England is one of America's great attractions. Come and enjoy it with us! We have attempted to supplement Mother Nature's visceral pleasure by providing challenge for the intellect as entertainment and refreshment for periodic relaxation of the mind and body. To get things started, the keynote speakers will provide the foundations for four important themes of the meeting: 1) The molecular biology of melanosome synthesis and function, 2) Novel approaches to the development of anti-melanoma vaccines and other treatments, 3) The origin, distribution and functional significance of ocular melanin, and 4) The nature and significance of programmed death (apoptosis) of normal melanocytes and melanoma cells. Symposia, mini-symposia and workshops will reflect not only these themes but also those inclusive of the broadest interests of the Society's members. The Sunrise Teaching Sessions will permit individuals specialized in one approach to pigment cell research to gain basic access to the vocabulary, methods and concepts of fellow members taking other approaches. The Program Committee has emphasized the importance of providing opportunities for social interaction throughout the scientific sessions. Social activity beyond the Westin Hotel will include the Annual Reception/Banquet at the Brown Faculty Club noted for its architecture and kitchen. An optional outing to the Haffenreffer Grant of Mt. Hope for a "clambake" will provide an opportunity for a glimpse of the historic buildings of Providence and Bristol, Rhode Island. You might consider lingering in the area for a few days, for historic Newport, Rhode Island and Boston and Cape Cod, Massachusetts are within an hour's drive.

The weather should be pleasant, neither too warm or too cool. So help to make the annual meeting a success by attending and actively participating in all of its functions.

For the Organizing Committee, Best Regards /s/ *Walter Quevedo* and *Harold Swartz*

## PROGRAM

### SUNDAY, JUNE 15

- 12:00 - 7:00 pm **Registration** (Meeting Hall Foyer, Westin Hotel)
- 12:00 - 2:00 pm **PASPCR Council Meeting**
- 12:00 - 2:00 pm **Setup and First Formal Poster Viewing Session**
- 2:00 pm **Greetings** - Donald J. Marsh, Dean of Medicine and Biological Sciences, Brown University
- 2:05 - 5:45 pm Symposium I: MOLECULAR ASPECTS OF MALIGNANT MELANOMA (Harold J. Wanebo and Frank L. Meyskens, Jr., co-chairs)**
- 2:05 pm NEW BIOLOGIC STRATEGIES IN THE TREATMENT OF MELANOMA AN OVERVIEW - **Harold J. Wanebo**.
- 2:30 pm **Keynote Address:** IDENTIFICATION OF HUMAN MELANOMA ANTIGENS RECOGNIZED BY TUMOR INFILTRATING T LYMPHOCYTES - THEIR USE FOR IMMUNOTHERAPY - **Yutaka Kawakami**.
- 3:15 pm REDOX RESPONSES IN NORMAL HUMAN MELANOCYTES AND METASTATIC MELANOMA - **Frank L. Meyskens Jr.**, Julie A. Buckmeier, Nilou Tohidian and Hung V. Chau.
- 3:35 pm IMMUNE RESPONSE TO MELANOSOMAL DIFFERENTIATION ANTIGEN INDUCED BY ALTERED ANTIGEN - **Shirley M. Bartido**, Isao Hara, Clarissa Naftzger, Siqun Wang, Lawrence Weber, George Yang, Yiqing Xu, Vijayasradhi Setaluri, Jie Qin, Yoichi Moroi and Alan N. Houghton.
- 3:55 pm Break
- 4:10 pm MONITORING OF GENE EXPRESSION IN MELANOMA CELLS DURING THE EARLY STEPS OF METASTASIS - **Toshihiro Shioda**, Lance L. Munn, Martin H. Fenner, Rakesh K. Jain and Kurt J. Isselbacher.
- 4:25 pm PREVENTION OF PRIMARY MELANOMA TUMOR GROWTH AND LUNG METASTASES USING VACCINES AND LYMPHOKINES - **David P. Shryer**, Hendrick Bogaars, Vincent J. Hearing and Harold J. Wanebo.
- 4:40 pm PROMOTER ACTIVITY OF MELANOCYTE-SPECIFIC GENE 1 (MSG1) CORRELATES WITH PIGMENTATION IN MOUSE MELANOMA CELL LINES - **Martin H. Fenner**, Julia E. Parrish, David L. Nelson, Kurt J. Isselbacher and Toshihiro Shioda.
- 4:55 pm MSG1, A MELANOCYTE-SPECIFIC NUCLEAR PROTEIN, IS INDUCED BY PHORBOL ESTER AND ACTIVATES TRANSCRIPTION - **Toshihiro Shioda**, Martin H. Fenner and Kurt J. Isselbacher.
- 5:10 pm REGULATION OF FGF-2 EXPRESSION IN SK-MEL-2 MELANOMA CELLS BY THE c-MYB PROTO-ONCOPROTEIN - **Mark R. Miglarese**, Ruth Halaban and Neil W. Gibson.
- 5:25 pm ABERRANT RETENTION OF TYROSINASE IN THE ENDOPLASMIC RETICULUM MEDIATES ACCELERATED DEGRADATION OF THE ENZYME AND CONTRIBUTES TO THE DEDIFFERENTIATED PHENOTYPE OF AMELANOTIC MELANOMA CELLS - **Ruth Halaban**, Elain Cheng, Yuhua Zhang, Gisela Moellmann, Douglas Hanlon, Marek Michalak, Vijayasradhi Setaluri and Daniel N. Hebert.
- 5:45 - 6:15 pm **General Assembly**
- 6:15 - 7:30 pm **Reception** (light refreshments)
- 7:30 pm **Evening Free** (poster viewing)

MONDAY, JUNE 16

- 7:00 - 8:15 am **Sunrise Session #1 (and continental breakfast)**  
MOUSE GENETICS SYSTEMS: AN INTRODUCTION TO THE USE OF MOUSE GENETICS RESOURCES IN MOLECULAR AND DEVELOPMENTAL PIGMENT CELL RESEARCH - **Murray Brilliant and Greg Barsh**
- 8:30 - 11:15 am **Minisymposium I: PIGMENT CELL GENETICS AND MOLECULAR BIOLOGY (Murray Brilliant and Greg Barsh, co-chairs)**
- 8:30 am ROLE OF MITF IN MELANOCYTE DEVELOPMENT - Karin Opdecamp, Minh-Thanh Nguyen, Atsuo Nakayama and **Heinz Arnheiter**.
- 9:05 am THE MOUSE PALE EAR (*ep*) MUTATION IS A MODEL FOR HERMANSKY-PUDLAK SYNDROME (HPS) - **Murray H. Brilliant**, John M. Gardner, Scott C. Wildenberg, Edward K. Novak, Michael E. Rusiniak, Richard T. Swank, Natalie M. Keiper, Neelu Puri, Nobuko Hagiwara, Joshua N. Finger, Anne L. Lehman and Richard A. King.
- 9:25 am IDENTIFICATION OF A NOVEL cDNA ASSOCIATED WITH THE HERMANSKY-PUDLAK SYNDROME (HPS) - **Scott C. Wildenberg**, James P. Fryer, John M. Gardner, William S. Oetting, Richard T. Swank, Murray H. Brilliant and Richard A. King.
- 9:45 am GENETIC REGULATION OF MELANOCYTE PATTERNING - H. Rhim, M. Cheng, S. Tilghman and **William Pavan**.
- 10:00 am Break
- 10:30 am ALTERNATIVE SPLICING IN NORMAL HUMAN MELANOCYTES - James P. Fryer, Raymond E. Boissy, Richard A. King and **William S. Oetting**.
- 10:45 am ACTIVATION OF TRP-2 EXPRESSION: REGULATION BY CELL DENSITY IN CULTURE AND *IN VIVO* EXPRESSION IN TRANSGENIC MICE - **Thomas J. Hornyak** and Edward B. Ziff.
- 11:00 am THE USE OF cDNA MICROARRAYS TO ANALYZE MELANOCYTE DEVELOPMENT AND FUNCTION - **Ulrike Teichmann**, M. Bittner, J. Trent and W. Pavan.
- 11:15 - Noon & 1:15 - 3:15 pm **Symposium II: ROLE OF MELANOCYTE DEATH DURING DEVELOPMENT AND ADAPTIVE RESPONSES OF SKIN TO DAMAGING AGENTS (Raymond A. Boissy and William Pavan, co-chairs)**
- 11:15 am **Keynote Address: A MODEL SYSTEM FOR STUDYING CELL DEATH REGULATION - James H. Wyche**
- 12:00 - 1:15 pm **Poster Session #2 and Lunch (on your own)**
- 1:15 pm ELUCIDATION OF THE SIGNALING PATHWAY WHICH MEDIATES THE RESPONSES OF HUMAN MELANOCYTES TO UVB LIGHT - Sungbin Im, Osamu Moro and **Zalfa Abdel-Malek**.
- 1:30 pm THE EFFECTS OF TYROSINASE ACTIVITY AND COMMONLY USED MITOGENS ON THE CYTOTOXICITY OF 4-TERTIARY BUTYL PHENOL TO HUMAN MELANOCYTES - **Fan Yang** and Raymond Boissy.
- 1:45 pm MET-HGF SIGNALING IS CRITICAL FOR MELANOCYTE DEVELOPMENT: IMPLICATIONS FOR WAARDENBURG SYNDROME TYPE II - Lidia Kos, Carola Ponzetto, Glenn Merlino and **William Pavan**.
- 2:00 pm PHYSICAL MAPPING AND EMBRYOLOGICAL ANALYSIS OF *DOMINANT MEGACOLON*, A MOUSE MODEL OF HIRSCHSPRUNG'S DISEASE - **E. Michelle Southard-Smith**, Lidia Kos and William J. Pavan.
- 2:15 pm EFFECTS OF AGOUTI ALLELES, HAIR PLUCKING, AND AGING ON THIOL (CYS AND GSH) CONCENTRATIONS IN MOUSE LIVERS - J.T. Brunz, R.N. Reese and **N.H. Granholm**.

- 2:30 pm DO VIRUSES AND/OR GROWING ENVIRONMENT AFFECT THE EXPRESSION OF AUTOIMMUNE VITILIGO IN THE SMYTH LINE CHICKEN? - **J. Robert Smyth Jr.**, Gisela F. Erf and G. P. Sreekumar.
- 2:45 pm PIGMENT SYNTHESIS AND MOLECULAR MECHANISMS OF COLOR PATTERN FORMATION IN BUTTERFLY WINGS - **P. Bernhardt Koch**.
- 3:00 pm FURTHER ANALYSIS OF GENETIC SENSITIVITY CAUSING PREMATURE CELL DEATH IN VITILIGINOUS AVIAN MELANOCYTES: LOW ANTIOXIDANT PROTECTION - **Roger R. Bowers**, Bao Nguyen and Sherri Buckner.
- 3:15 pm Break
- 3:35 - 5:50 pm** **Minisymposium II: SIGNALING PATHWAYS IN PIGMENT REGULATION**  
(**Zalfa Abdel-Malek and Ana Maria Castrucci, co-chairs**)
- 3:35 pm SIGNAL TRANSDUCTION IN NON-MAMMALIAN PIGMENT CELLS - **Ana Maria de Lauro Castrucci**, Alice Reis de Oliveira and Luiz Eduardo Maia Nery.
- 3:55 pm ECTOPIC EXPRESSION OF DOMINANT-NEGATIVE E2F1 IN MELANOCYTES CONFERS TPA-INDEPENDENT GROWTH - **Ruth Halaban**, Elaine Cheng, Yuhua Zhang and Christopher Mandigo.
- 4:15 pm INTRACELLULAR SIGNALLING PATHWAYS REGULATING MELANOGENESIS - **Hee-Young Park**.
- 4:35 pm THE EXTRACELLULAR MATRIX AND GROWTH FACTORS AS COMPLIMENTARY SIGNALING MOLECULES IN MELANOCYTE BIOLOGY: FROM APOPTOSIS TO THE CYTOSKELETON - **Glynis A. Scott** and Linda Cassidy.
- 4:55 pm ROLE OF THE CDK-INHIBITORS p27<sup>KIP-1</sup>, AND p16<sup>INK4</sup> AND THE TRANSCRIPTION FACTOR E2F-1 IN MELANOCYTE TERMINAL DIFFERENTIATION - Maher Haddad, Fu Liao, Weidong Xu and **Estela E. Medrano**.
- 5:15 pm SIGNALING PATHWAYS ACTIVATED BY  $\alpha$ -MSH AND ENDOTHELIN-1: IMPLICATIONS ON THE REGULATION OF HUMAN MELANOCYTE PROLIFERATION AND MELANOGENESIS - Akihiro Tada and **Zalfa Abdel-Malek**.
- 5:35 pm IDENTIFICATION OF NOVEL GENES MODULATED DURING PHEOMELANOGENESIS BY DIFFERENTIAL DISPLAY AND SUBTRACTIVE HYBRIDIZATION - **Minao Furumura**, Chie Sakai, Michael Ollmann, S. Brian Potterf, Wilfred Vieira, Gregory S. Barsh and Vincent J. Hearing.
- 7:00 - 10:00 pm "Clambake/Steak fry" (optional)

## TUESDAY, JUNE 17

**8:00 am - 5:00 pm Registration (Ballroom Foyer)**

**7:00 - 8:15 am Sunrise Session #2 (and continental breakfast)**

MELANOCYTE MELANOGENESIS AND POPULATIONS IN THE GENERATION OF CONSTITUTIVE AND FACULTATIVE SKIN COLOR - **James J. Nordlund**

**8:30 - 11:45 am Symposium III: MELANOSOMES: BIOGENESIS AND STRUCTURE (Vincent J. Hearing and John Hammer, co-chairs)**

8:30 am BIOGENESIS OF MELANOSOMES AND THE PINKEYED DILUTION GENE PRODUCT - **Seth J. Orlow**, S. Rosemlat, E. Sviderskaya, D.J. Easty, A. Wilson and D.C. Bennett.

8:50 am TRAFFICKING OF MELANOSOMAL PROTEINS - **Vijayasradhi Setaluri**.

9:10 am **Keynote Address (Gelb Lecture):** STRUCTURAL AND ENZYMATIC COMPONENTS OF EU-AND PHEOMELANOSOMES - **Vincent J. Hearing**.

- 9:45 am THE ROLE OF MYOSIN V IN THE MOVEMENT OF MELANOSOMES IN MURINE MELANOCYTES - Xufeng Wu, Qin Wei, Blair Bowers, Bob Kocher and **John A. Hammer III**.
- 10:05 am TRANSFER OF MELANOSOMES TO KERATINOCYTES - **Jag Bhawan**.
- 10:25 am Break
- 10:45 am IDENTIFICATION AND CHARACTERIZATION OF A NOVEL 65kDa MELANOSOMAL PERIPHERAL MEMBRANE PROTEIN- **Preminda Samaraweera**, P. Donatien, V.J. Hearing, T. Kobayashi, J.J. Panthier and S.J. Orlow.
- 11:00 am MUTATIONAL ANALYSIS OF THE MODULATION OF TYROSINASE ACTIVITY BY TRP-1 - **Kiyoshi Sato**, F. Beermann, L. Lamoreux and S.J. Orlow.
- 11:15 pm REGULATION OF MELANIN PRECURSOR RATIOS: MELANOSOMAL TRANSPORT OF CYSTEINE AND GLUTATHIONE - **S. Brian Potterf**, Messod Benathan, Chie Sakai, Minao Furumura and Vincent J. Hearing.
- 11:30 am CYTOSOLIC COMPONENTS ALTER TYROSINE UPTAKE BY MELANOSOMES *IN VITRO* - **Mary K. Cullen**, Maria I. Colombo and Philip D. Stahl.
- 11:45 - 1:00 pm **Poster Session #3 and Lunch** (on your own)
- 1:00- 4:15 pm** **Minisymposium III: COMPARATIVE ASPECTS OF VERTEBRATE PIGMENTATION** (**Joseph T. Bagnara and Sally Frost-Mason, co-chairs**)
- 1:00 pm COMPARATIVE ASPECTS OF NON-MAMMALIAN PIGMENTATION - **Joseph T. Bagnara**.
- 1:20 pm THE COMPARATIVE MOLECULAR BIOLOGY, GENETICS AND EVOLUTION OF AXOLOTL PIGMENT CELLS - **Kenneth A. Mason**.
- 1:40 pm COMPARATIVE ASPECTS OF NON-MAMMALIAN PIGMENTATION: REGULATION OF PIGMENT CELLS - **Mac E. Hadley**.
- 2:00 pm THE MELANOGENIC POTENTIAL OF EARLY- VERSUS LATE-EMIGRATING NEURAL CREST CELLS DICTATES THEIR MORPHOGENETIC BEHAVIOR - **Mark V. Reedy**, Cloris D. Faraco and Carol A. Erickson.
- 2:15 pm DEVELOPMENTALLY REGULATED EXPRESSION OF TYROSINASE RELATED PROTEIN-1 IN *AMBYSTOMA MEXICANUM*- **Mark W. Moody** and Giselle Thibaudeau.
- 2:30 pm REGION-SPECIFIC INFLUENCES AND DEVELOPMENTAL REGULATION OF XANTHOPHORE DIFFERENTIATION - **Susan Holder** and Giselle Thibaudeau.
- 2:45 pm CLONING AND MOLECULAR CHARACTERIZATION OF TWO GENES INVOLVED IN THE REGULATION OF PHEOMELANOGENESIS FROM THE DOMESTICATED DOG - **J M. Newton** and Gregory S. Barsh.
- 3:00 pm GENETIC AND MOLECULAR LINKAGE ANALYSIS OF THE SMYTH LINE CHICKEN MODEL FOR AUTOIMMUNE HUMAN VITILIGO - **G.P. Sreekumar**, J.R. Smyth, Jr. and F. Abel Ponce de Leon.
- 3:15 pm Break
- 3:45 pm COMPARATIVE PHYSIOLOGY OF FISH CHROMATOPHORES - **Ana Maria de Lauro Castrucci** and Maria Aparecida Visconti.
- 4:00 pm PHOTOTRANSDUCTION IN *XENOPUS* MELANOPHORES - **Mark D. Rollag**, Ignacio Provencio and Guisen Jiang.
- 4:15 - 6:00 pm** **Minisymposium IV: PHOTOBIOLOGY AND BIOPHYSICS OF MELANIN AND MELANOCYTES** (**Helene Z. Hill and Harold M. Swartz, co-chairs**)

- 4:15 pm      ROLE OF INTRACELLULAR PIGMENT IN RESPONSES TO SOLAR RADIATION: ARE WE BARKING UP THE WRONG TREE? - Helene Z. Hill, Weixiong Li and **Jaskiran Kaur**.
- 4:35 pm      CHEMICAL REGULATION OF EU-AND PHEO-MELANOGENESIS - **Shosuke Ito**, Kazumasa Wakamatsu and Hiroyuki Ozeki.
- 4:55 pm      IDENTIFICATION OF FREE RADICALS IN MELANINS: STUDY OF FREE RADICAL MODELS FOR EUMELANIN AND PHEOMELANIN - **Mark J. Nilges**, Tadeusz Sarna, Barbara Pilas and Harold M. Swartz.
- 5:15 pm      THE REACTION BETWEEN FERRITIN AND L-DOPA: A MODEL FOR NEUROMELANIN BIOSYNTHESIS - **Jeffrey M. Tosk**, Anita K. Go, Gerardo Perez, Traci J. Winters, Tomasz Panz and Harold M. Swartz.
- 5:30 pm      XAFS STUDIES OF Fe SITES IN SYNTHETIC AND NATURAL NEUROMELANIN - **M. Eisner**, S.C. Moss, A.J. Kropf, B.A. Bunker, L. Zecca, A. Struppolo and R. Crippa.
- 5:45 pm      REDOX BUFFERING BY FUNGAL MELANIN AND FE(II) - **Eric S. Jacobson** and Joann D. Hong.
- 7:00 - 10:00 pm      **Reception and Banquet**, Brown Faculty Club

**WEDNESDAY, JUNE 18**

- 7:00 - 8:15 am      Sunrise Session #3 (and continental breakfast)**  
CHEMISTRY AND BIOCHEMISTRY OF MELANOGENESIS - **Vincent J. Hearing and Shosuke Ito**
- 8:30 - 12:05 pm      Symposium IV: OCULAR MELANOCYTES AND RPE - ROLE OF TRANSCRIPTION FACTORS IN PIGMENT CELL BIOLOGY (Seth J. Orlow and James Nordlund, co-chairs)**
- 8:30 am      **Keynote Address: EFFECTS OF MICROPHTHALMIA TRANSCRIPTION FACTOR AND KIT GENES ON PIGMENT CELLS OF EYE AND SKIN IN THE VITILIGO MUTANT MOUSE - Richard L. Sidman**
- 9:15 am      ANALYSIS OF TYROSINASE AND TYROSINASE RELATED PROTEINS IN THE RPE/CHOROID OF VITILIGO (mi<sup>-vit</sup>/mi<sup>-vit</sup>) MICE - **Sylvia B. Smith**, B.K. Zhou and Seth J. Orlow.
- 9:35 am      ISOLATION AND CHARACTERIZATION OF A MICROPHTHALMIA INTERACTING PROTEIN THAT INHIBITS TYROSINASE EXPRESSION IN HUMAN MELANOCYTES - Hirofumi Aokil, Ohji Ifuku and **Antonis S. Zervos**.
- 9:55 am      Break
- 10:25 am      RELATIONSHIP BETWEEN TYROSINASE/MELANIN LEVELS AT BIRTH AND RETINAL PATHWAYS IN DARK-EYED ALBINO MICE - **Rivka A. Rachel** and Carol A. Mason.
- 10:45 am      REGULATION OF GROWTH AND MELANOGENESIS OF UVEAL MELANOCYTES *IN VITRO* - **Dan-Ning Hu** and Steve A. McCormick.
- 11:05 am      OCULAR MELANOCYTES EXPRESS  $\beta$ -ADRENERGIC RECEPTOR AND RESPOND TO AUTONOMIC NEUROTRANSMITTERS - Huiquan Zhao, Li Li, **Raymond E. Boissy** and James J. Nordlund.
- 11:25 am      MODULATION OF TYROSINE TRANSPORT INTO MELANOSOMES MAY REGULATE RESPONSES TO MELANOGENIC STIMULANTS - **S. Brian Potterf** and Vincent J. Hearing.
- 11:45 pm      PROTEIN GLYCOSYLATION IN THE REGULATION OF MELANOGENESIS - **S.A. Sodi**, **A.K. Chakraborty**, Y. Avissar, S.J. Orlow, M. Rachkovsky, S. Rosemblat, A. Keh-Yen, J. L. Bolognia and J. M. Pawelek.
- 12:05- 1:00 pm      **Business Meeting and Presentation of Awards**



## POSTERS

SPACIAL & TEMPORAL DIFFERENCES IN MELANOCYTIC MIGRATORY PATHWAYS OF EMBRYONIC MICE - **Karen J. Dunn** and William J. Pavan

STRAIN-SPECIFIC WHITE-SPOTTING PATTERNS IN LABORATORY MICE - **Dong Fang**, William J. Pavan and M. Lynn Lamoreux.

EFFECT OF CELL-CELL INTERACTION ON THE PRODUCTION OF PROOPIOMELANOCORTIN PEPTIDES *IN VITRO* AND *IN VIVO* - **Jamal Farooqui**, Gong Can, Steve Boyce, Glenn Warden and James Nordlund.

THE CHANGES IN THE PROLIFERATION AND DIFFERENTIATION OF PRIMARY CULTURED EPIDERMAL MELANOCYTES DURING THE DEVELOPMENT OF PIGMENTED SPOTS INDUCED BY UVB IRRADIATION - **Rikako Furuya**, Satoru Akiu, Masako Naganuma, Minoru Fukuda and Tomohisa Hirobe.

MELANOTROPIN PEPTIDES, RECEPTORS, AND ANTAGONISTS - **Mac E. Hadley** and Victor J. Hruby.

CELL SIGNALING DURING DEVELOPMENT OF THE MELANOPHORE IN ZEBRAFISH - **Eun-Jung Jin** and Giselle Thibaudeau.

THE LINKAGE BETWEEN POLYMORPHIC GA REPEAT SEQUENCE AND PATHOLOGICAL MUTATIONS OF THE TYROSINASE GENE IN JAPANESE OCA1 PATIENTS - **Jun Matsunaga**, Miwako Hara-Dakeishi, Yoshinori Miyamura, Eriko Nakamura, Muneo Tanita, Yasuko Takisawa, Hiroshi Shimizu, Takeji Nishikawa and Yasushi Tomita.

DIFFERENTIAL EXPRESSION STUDIES OF THE WHITE MUTANT OF THE MEXICAN AXOLOTL - **Nathan B. Parker** and Kenneth A. Mason.

TYPE 2 OCULOCUTANEOUS ALBINISM (OCA2) IN ZIMBABWE AND CAMEROON: DISTRIBUTION OF THE 2.7 KB DELETION ALLELE OF THE P GENE - **Neelu Puri**, Donna Durham-Pierre, Robert Aquaron, Patricia M. Lund, Richard A. King and Murray Brilliant.

MODELING FOR MELANOCYTE LIFE AND DEATH IN *LIGHT* AND *SILVER* MICE: THE COMPLEXITY OF GENE INTERACTIONS - Walter C. Quevedo, Jr., **Thomas J. Holstein**, Jacob Dyckman and Charles J. McDonald.

## ADDED AT THE PRESS:

THE INVOLVEMENT OF LDH INHIBITION AND THE KREBS CYCLE IN PIGMENT INHIBITION IN THE B16 MOUSE MELANOMA CELL LINE BY AHAS AND OTHER METABOLIC INTERMEDIATES - **Alan D. Heath**.

PRELIMINARY OBSERVATIONS ON THE PARTICIPATION OF TAIL EPIDERMIS IN DORSAL SPOT PATTERN FORMATION IN THE LARVAE OF THE LEOPARD FROG, *Rana pipiens* - **John C. Naughten**.

---

## Pigment Cell Research Wants YOU!

by James J Nordlund

### THE PRICE OF THE JOURNAL *PIGMENT CELL RESEARCH* COMES TUMBLING DOWN

Hope that the stock markets don't crash like the cost of our pigment journal. Your subscription to ***Pigment Cell Research*** will be about 45% less than in previous years. The real price was over \$200 but most were getting it at discount for about \$160. At the recent meeting in Anaheim, Munskgaard agreed to revise its pricing schedule for the journal ***Pigment Cell Research*** for Society members only. For an annual fee of \$95 total you can have your own copy of ***Pigment Cell Research***, the official journal of the International Federation of Pigment Cell Societies.

You get a lot for this small price. For example, you will get the bimonthly issues of the latest and best of pigment biology. In addition you will get the proceedings of the meeting of the European Society for Pigment Cell Research to be held in France later this year. You will

get the proceedings of the upcoming PASPCR meeting in Providence, RI under the chairmanship of Walt Quevedo. You will get the proceedings of the XVI<sup>th</sup> meeting including the abstracts and the published manuscripts.

We need everyone's support. We need to get most of the members subscribing to keep this journal flourishing. Joe Bagnara did a yeoman's job getting it up and started and Dr. Jiro Matsumoto is doing a great job making the issues bigger and better.

An application for the journal will be included with your dues statement for 1997.

**SUPPORT YOUR JOURNAL AND SOCIETY. SUBSCRIBE TO THE JOURNAL WHEN YOU  
RENEW YOUR MEMBERSHIP TO PASPCR.**

---

## **Invitation to the XVII<sup>th</sup> IPCC (International Pigment Cell Conference)**

**by Shosuke Ito**

**Invitation to the XVII<sup>th</sup> International Pigment Cell Conference      Nagoya Congress Center  
Nagoya, Japan      October 30 - November 3, 1999**

Dear Colleague:

After the inauguration of the International Federation of Pigment Cell Societies (IFPCS) in Kobe in 1990, the International Pigment Cell Conferences (IPCC) rotate among the European, American, and Asian continents, hosted by one of the three regional societies: the ESPCR, the JSPCR, and the PASPCR. The 15<sup>th</sup> IPCC was thus held in London in 1993, chaired by Professor Patrick A. Riley, and the 16<sup>th</sup> IPCC was recently held in Anaheim, California, chaired by Professor Frank L. Meyskens, Jr.

It is our great honor and real pleasure to inform you that the next 17<sup>th</sup> IPCC will be held in Nagoya, Japan in 1999, co-organized by the IFPCS and the JSPCR. We heartily hope that pigment cell biologists and clinicians will join together in Nagoya in October 1999 to present their latest achievements in the exciting world of pigment cell research. Your participation will be most important for the scientific success of this meeting.

The city of Nagoya, the 4<sup>th</sup> largest in Japan, enjoys a rich history of traditional culture and a reputation for world-renowned high-tech industries. Nagoya is located at the center of Japan and is easy to access: the Nagoya International Airport is directly connected with 30 cities around the world. The conference site, the Nagoya Congress Center, is newly built and has ample spaces for the participants to discuss and exchange ideas, which we believe will certainly bring about fruitful collaborations.

We will follow the good tradition of the IFPCS leadership in directing scientific programs to unify the three regional societies. Within such a framework, we wish to place special emphasis on poster presentations. We hope to provide a certain number of travel grants for young investigators to attend this meeting. In order to be eligible for such a grant, an applicant has to be a member of one of the three regional societies for at least one year prior to the meeting. We are also planning banquet and social activities in such a way to make your visit to Nagoya most enjoyable and memorable. It will be our great privilege to welcome you and your colleagues to Nagoya in 1999.

Shosuke Ito, Ph.D.

Kazumasa Wakamatsu, Ph.D.

*Chair, IPCC Nagoya*

*Secretary-General, IPCC Nagoya*

For further information please contact us at: Fujita Health University School of Health Sciences, Toyoake, Aichi 470-11, Japan; *Phone:* +81-562-93-2595; *Fax:* +81-562-93-4595; *Email:* sito@fujita-hu.ac.jp

---

## Positions - Wanted and Available :

**Summer Internship** - Johnson & Johnson Consumer Products Worldwide is located in Skillman, NJ. Its primary business are baby care, wound care and skin care. Its Drug Development group is responsible for research leading to new prescriptions (Ortho Dermatology) and consumer skin care products. Project Description: Pigmentation project, looking into molecular and cellular events that regulate melanogenesis. Qualifications: Ph.D. student or post-doctoral fellow in molecular biology with strong interest in skin biology desired. Start Date: Spring/Summer 1997 (up to 12 weeks) Salary: We offer a competitive salary of \$2,600/month and relocation assistance. Interns also have use of our on-site fitness centers. Mentor: Miri Seiber, Ph.D. (908) 874-2325 Contact/Send Resumes to: Nancy Warrick (INT-1), Johnson & Johnson, Corporate College Relations, 501 George Street, New Brunswick, NJ 08901, Tel: (908) 524-3229, FAX: (908) 524-3141.

**Assistant Professor** - The Department of Physiology at the University of Sao Paulo has an open position for assistant professor. Applications will be received until June 1<sup>st</sup>. A Ph.D. is required and post-doctoral experience is desirable. The selection will be held during the first week of July with the candidates' presence. The curriculum vitae including copies of the publications, the Ph.D. certificate and a research project on Human or Animal Physiology (including biochemical and biomolecular approaches) should accompany the application. A lecture (undergraduate level) on a picked out subject of one of three areas (Neurosensory and Muscle Physiology; Cardiorespiratory and Excretory Physiology; Nutrition, Metabolism and Endocrine Physiology) chosen by the candidate should be given to the Selection Committee, that will also interview the candidates. Please contact: Ana Maria de L. Castrucci, Dep. Physiology, Inst. Biosciences, University of Sao Paulo, CP11176, CEP 05422-970, Sao Paulo, Brasil; Fax 5511 818-7422 phone 5511 818-7610 Email AMDLCAST@USP.BR

**Predoctoral and Postdoctoral Positions** - available for molecular biologists in the areas of drug discovery and metabolism research. Requires experience in gene cloning, DNA sequencing, recombinant protein expression and cell culture methods. Prior experience in dermatology research is desirable. Southern Research Institute is a diversified research and development organization. Our Life Sciences Division provides comprehensive preclinical drug development and testing capabilities as well as basic research in drug design and synthesis, pharmaceutical formulations, toxicology, virology, microbiology, and pharmacology. To apply, send resume or curriculum vitae to: Southern Research Institute, Attention: Suzann Allen, Human Resources, Department 118, P.O. Box 55305, Birmingham, AL, 35255-5305.

**Faculty Position** - Massachusetts General Hospital, Harvard Medical School, Cutaneous Biology Research Center. The Cutaneous Biology Research Center (CBRC) seeks a molecular, cellular or developmental biologist to establish a program in fundamental research relevant to skin pigmentation. Areas of research can include but are not limited to pigment synthesis and transfer in melanocytes, genetics of mouse coat color and development/migration of neural crest cells. Applicants must have a Ph.D. and/or M.D. degree and relevant postdoctoral experience. Only applicants with a strong research record and the potential to develop extramurally supported research programs will be considered. Individuals with a demonstrated ability to develop imaginative approaches to important biological questions are particularly encouraged to apply. Rank/salary/start-up funds and space are negotiable depending on experience and qualifications. The CBRC occupies 45,000 square feet of fully equipped laboratory space in a new multidisciplinary research facility. Interested individuals should send curriculum vitae, reprints, a statement of research and future directions, along with the names, addresses and telephone numbers of three references to: Dr. Paul F. Goetinck, Chair, Faculty Search Committee, Cutaneous Biology Research Center, Massachusetts General Hospital - East, Building 149, 13th Street, Charlestown, MA 02129

---

## INTERPIG DataBase

by Vincent Hearing

The INTERPIG database is on the InterNet! You can now access the InterPig DataBase at the following address: <http://lenti.med.umn.edu/paspcr/interpig.html>. Please note that as of this time, I estimate that less than 5% of the various IFPCS members have contributed entries. Think of how useful and complete this list would be if everyone took the time to supply their own information.

Please take a moment to fill out the database data entry form (either online through the Web page or via Email) and send it back to Dr. Hearing. Please contact Vince Hearing or Bill Oetting if you need more information about these mechanisms of submission.

**Check out the New Table on Pigment Genes & Associated Diseases !!!**

---

## Bibliography :

The Bibliography published in this issue covers the period February, 1996 through April, 1996. If you notice a paper that was not detected by this search that should be included, please send it to us and we will include it in the next issue. We have attempted to highlight any publications which include a member of the PASPCR with a star (*sorry if we missed you but let us know and you'll get a free marked repeat in the next issue*).

### MELANINS, MELANOGENS & MELANOGENESIS

- Bergstrom M, Lu L, Marquez M, Fasth KJ, Bjurling P, Watanabe Y, Eriksson B, Langstrom B: Modulation of organ uptake of C-11-labelled L-DOPA. *Nucl Med Biol* 24:15-19 (1997).
- Bessou S, Pain C, Taieb A: Use of human skin reconstructs in the study of pigment modifiers. *Arch Dermatol* 133:331-336 (1997).
- Borovansky J, Mommaas AM, Smit NPM, Eygendaal D, Winder AJ, Vermeer PJ, Pavel S: Melanogenesis in transfected fibroblasts induces lysosomal activation. *Arch Dermatol Res* 289:145-150 (1997).
- Bossinakou KS, Mantzouridis TD, Fragoulis EG: L-dopa decarboxylase mRNA levels are correlated with the L-dopa decarboxylase protein profile during the development of the insect *Ceratitidis capitata*. *Insect Biochem Molec Biol* 26:859-865 (1996).
- Calne DB, delaFuenteFernandez R, Kishore A: Contributions of positron emission tomography to elucidating the pathogenesis of idiopathic parkinsonism and dopa responsive dystonia. *J Neural Transmission Suppl* 47-52 (1997).
- ❖ Castanet J, Ortonne JP: Hair melanin and hair color. *Formation and Structure of Human Hair* 209-225:225 (1997).
- ❖ Castrucci AMD, Almeida ALK, AlObeidi FA, Hadley ME, Hrubby VJ, Staples DJ, Sawyer TK: Comparative biological activities of  $\alpha$ -MSH antagonists in vertebrate pigment cells. *Gen Comp Endocrinol* 105:410-416 (1997).
- Faucheux BA, Hauw JJ, Agid Y, Hirsch EC: The density of I-<sup>125</sup>-transferrin binding sites on perikarya of melanized neurons of the substantia nigra is decreased in Parkinson's disease. *Brain Res* 749:170-174 (1997).
- Foppoli C, Coccia R, Cini C, Rosei MA: Catecholamines oxidation by xanthine oxidase. *Bba Gen Subjects* 1334:200-206 (1997).
- Kamei H, Koide T, Kojima T, Hasegawa M, Umeda T: Suppression of growth of cultured malignant cells by allomelanins, plant-produced melanins. *Cancer Biother Radiopharm* 12:47-49 (1997).
- Kinley JS, Brunborg G, Moan J, Young AR: Photoprotection by furocoumarin-induced melanogenesis against DNA photodamage in mouse epidermis *in vivo*. *Photochem Photobiol* 65:486-491 (1997).
- ❖ Li WX, Hill HZ: Induced melanin reduces mutations and cell killing in mouse melanoma. *Photochem Photobiol* 65:480-485 (1997).
- MartinezEsparza M, JimenezCervantes C, Beermann F, Aparicio P, Lozano JA, GarciaBorron JC: Transforming growth factor- $\beta$  1 inhibits basal melanogenesis in B16/F10 mouse melanoma cells by increasing the rate of degradation of tyrosinase and tyrosinase-related protein-1. *J Biol Chem* 272:3967-3972 (1997).
- Mohankumar PS, Thyagarajan S, Quadri SK: Tyrosine hydroxylase and DOPA decarboxylase activities in the medial preoptic area and arcuate nucleus during the estrous cycle: Effects of aging. *Brain Res Bull* 42:265-271 (1997).
- Nakajima M, Shinoda I, Samejima Y, Miyauchi H, Fukuwatari Y, Hayasawa H:  $\kappa$ -Casein suppresses melanogenesis in cultured pigment cells. *Pigm Cell Res* 9:235-239 (1996).
- ❖ Ozeki H, Ito S, Wakamatsu K, Thody AJ: Spectrophotometric characterization of eumelanin and pheomelanin in hair. *Pigm Cell Res* 9:265-270 (1996).
- ❖ RomeroGraillet C, Aberdam E, Clement M, Ortonne JP, Ballotti R: Nitric oxide produced by ultraviolet-irradiated keratinocytes stimulates melanogenesis. *J Clin Invest* 99:635-642 (1997).
- Rozanowska M, Bober A, Burke JM, Sarna T: The role of retinal pigment epithelium melanin in photoinduced oxidation of ascorbate. *Photochem Photobiol* 65:472-479 (1997).
- Sakakibara Y, Katafuchi J, Takami Y, Nakayama T, Suiko M, Nakajima H, Liu MC: Manganese-dependent Dopa/tyrosine sulfation in HepG2 human hepatoma cells: Novel Dopa/tyrosine sulfotransferase activities associated with the human monoamine-form phenol sulfotransferase. *Bba Mol Cell Res* 1355:102-106 (1997).
- Schraermeyer U, Dohms M: Detection of a fine lamellar gridwork after degradation of ocular melanin granules by cultured peritoneal macrophages. *Pigm Cell Res* 9:248-254 (1996).

- Sidibe S, Saal F, RhodesFeuillette A, Lagaye S, Pelicano L, Canivet M, Peries J, Dianoux L: Effects of serotonin and melanin on *in vitro* HIV-1 infection. *J Biol Regulat Homeost Agent* 10:19-24 (1996).
- Takano Y, Kubo Y, Kawamura C, Tsuge T, Furusawa I: The *Alternaria alternata* melanin biosynthesis gene restores appressorial melanization and penetration of cellulose membranes in the melanin-deficient albino mutant of *Colletotrichum lagenarium*. *Fungal Genet Biol* 21:131-140 (1997).
- Yasumoto K, Yokoyama K, Takahashi K, Tomita Y, Shibahara S: Functional analysis of microphthalmia-associated transcription factor in pigment cell-specific transcription of the human tyrosinase family genes. *J Biol Chem* 272:503-509 (1997).

## MELANOCYTES & KERATINOCYTES

- Bizik J, Bessou S, Felnerova D, Vaheri A, Taieb A: The proteolytic potential of normal human melanocytes: Comparison with other skin cells and melanoma cell lines. *Pigm Cell Res* 9:255-264 (1996).
- Borchers AH, Sanders LA, Powell MB, Bowden GT: Melanocyte mediated paracrine induction of extracellular matrix degrading proteases in squamous cell carcinoma cells. *Exp Cell Res* 231:61-65 (1997).
- Carroll JM, Crompton T, Seery JP, Watt FM: Transgenic mice expression IFN- $\gamma$  in the epidermis have eczema, hair hypopigmentation, and hair loss. *J Invest Dermatol* 108:412-422 (1997).
- ❖ Chen D, Guo JR, Miki T, Tachibana M, Gahl WA: Molecular cloning and characterization of rab27a and rab27b, novel human rab proteins shared by melanocytes and platelets. *Biochem Mol Med* 60:27-37 (1997).
- Cook MG, Clarke TJ, Humphreys S, Fletcher A, McLaren KM, Stevens A, Theaker JM, Melia J: Melanocytic intra-epidermal neoplasia (MIN). *Histopathology* 30:196-197 (1997).
- Davis MDP, Harris KR, Earnest F, Gibson LE: Malignant blue nevus. *European J Dermatology* 7:53-55 (1997).
- ❖ DeDavid M, Orlow SJ, Provost N, Marghoob AA, Rao BK, Huang CL, Wasti Q, Kopf AW, Bart RS: A study of large congenital melanocytic nevi and associated malignant melanomas: Review of cases in the New York University Registry and the world literature. *J Am Acad Dermatol* 36:409-416 (1997).
- ❖ DeDavid M, Orlow SJ, Provost N, Marghoob AA, Rao BK, Wasti Q, Huang CL, Kopf AW, Bart RS: Neurocutaneous melanosis: Clinical features of large congenital melanocytic nevi in patients with manifest central nervous system melanosis. *J Am Acad Dermatol* 35:529-538 (1996).
- Delmonte S, Parodi A, Rebora A: Pigmentary demarcation lines type B in a white non- pregnant woman. *Acta Derm Venereol [Stockh]* 77:82(1997).
- Donois E, Freund O, SurleveBazeille JE, Taieb A: Stereological image analysis of cultured human melanocytes observed by transmission electron microscopy. *Microsc Res Technique* 36:188-200 (1997).
- Eisen D: Minocycline-induced oral hyperpigmentation. *Lancet* 349:400(1997).
- Fishman P, Merimski O, Baharav E, Shoenfeld Y: Autoantibodies to tyrosinase: The bridge between melanoma and vitiligo. *Cancer* 79:1461-1464 (1997).
- Grevelink JM, vanLeeuwen RL, Anderson RR, Byers HR: Clinical and histological responses of congenital melanocytic nevi after single treatment with Q-switched lasers. *Arch Dermatol* 133:349-353 (1997).
- Griesser J, Kaufmann D, Maier B, Mailhammer R, Kuehl P, Krone W: Post-transcriptional regulation of neurofibromin level in cultured human melanocytes in response to growth factors. *J Invest Dermatol* 108:275-280 (1997).
- Happle R, Koopman RJJ: Becker nevus syndrome. *Am J Med Genet* 68:357-361 (1997).
- Ishii S, Nagase T, Tashiro F, Ikuta K, Sato S, Waga I, Kume K, Miyazaki J, Shimizu T: Bronchial hyperreactivity, increased endotoxin lethality and melanocytic tumorigenesis in transgenic mice overexpressing platelet-activating factor receptor. *EMBO J* 16:133-142 (1997).
- ❖ Jiang JW, Sharma SD, Hrubby VJ, Bentley DL, Fink JL, Hadley ME: Human epidermal melanocyte and keratinocyte melanocortin receptors: Visualization by melanotropic peptide conjugated microspheres (Latex beads). *Pigm Cell Res* 9:240-247 (1996).
- Kluppel M, Nagle DL, Bucan M, Bernstein A: Long-range genomic rearrangements upstream of Kit dysregulate the developmental pattern of Kit expression in W-57 and W-banded mice and interfere with distinct steps in melanocyte development. *Development* 124:65-77 (1997).
- Kollias N, Gillies R, CohenGoihman C, Phillips SB, Muccini JA, Stiller MJ, Drake LA: Fluorescence photography in the evaluation of hyperpigmentation in photodamaged skin. *J Am Acad Dermatol* 36:226-230 (1997).
- ❖ LePoole IC, VandenBerg FM, VandenWijngaard RMJGJ, Galloway DA, VanAmstel PJ, Buffing AAM, Smits HL, Westerhof W, Das PK: Generation of a human melanocyte cell line by introduction of HPV16 E6 and E7 genes. *In vitro Cell Dev Biol Animal* 33:42-49 (1997).
- Maeda K, Naganuma M: Melanocyte-stimulating properties of secretory phospholipase A(2). *Photochem Photobiol* 65:145-149 (1997).
- Marghoob AA, Kopf AW: Persistent nevus: An exception to the ABCD rule of dermoscopy. *J Am Acad Dermatol* 36:474-475 (1997).
- Nakajima M, Shinoda I, Samejima Y, Miyauchi H, Fukuwatari Y, Hayasawa H: A simple and quantitative cell-blotting assay for evaluation of pigmentation of cultured melanocytes and its use in demonstrating the depigmenting effect of lactoferrin. *Arch Dermatol Res* 289:180-183 (1997).
- Orel L, Simon MM, Karlseder J, Bhardwaj R, Trautinger F, Schwarz T, Luger TA:  $\alpha$ -Melanocyte stimulating hormone downregulates differentiation-driven heat shock protein 70 expression in keratinocytes. *J Invest Dermatol* 108:401-405 (1997).

- Pennoyer JW, Grin CM, Driscoll MS, Dry SM, Walsh SJ, Gelineau JP, GrantKels JM: Changes in size of melanocytic nevi during pregnancy. *J Am Acad Dermatol* 36:378-382 (1997).
- Pope TW, Williams WL, Wilkinson SB, Gordon MA: Textural parameters based on the Spatial Gray Level Dependence Method applied to melanocytic nevi. *Comput Biomed Res* 29:429-437 (1996).
- Raid K, Turnley AM, Maxwell GD, Kurihara Y, Kurihara H, Bartlett PF, Murphy M: Multiple roles for endothelin in melanocyte development: Regulation of progenitor number and stimulation of differentiation. *Development* 122:3911-3919 (1996).
- Rubegni P, Cevenini G, Flori ML, Fimiani M, Stanghellini E, Molinu A, Barbini P, Andreassi L: Relationship between skin color and sun exposure history: A statistical classification approach. *Photochem Photobiol* 65:347-351 (1997).
- Scott G, Cassidy L, Busacco A: Fibronectin suppresses apoptosis in normal human melanocytes through an integrin-dependent mechanisms. *J Invest Dermatol* 108:147-153 (1997).
- Slater DN: Melanocytic intra-epidermal neoplasia (MIN). *Histopathology* 30:195-196 (1997).
- Teunissen MBM, Koomen CW, Jansen J, Malefyt RD, Schmitt E, VandenWijngaard RMJGJ, Das PK, Bos JD: In contrast to their murine counterparts, normal human keratinocytes and human epidermoid cell lines A431 and HaCaT fail to express IL-10 mRNA and protein. *Clin Exp Immunol* 107:213-223 (1997).
- Ukita M, Hasegawa M, Nakahori T: Trisomy 18 mosaicism in a woman with normal intelligence, pigmentary dysplasia, and an 18 trisomic daughter. *Am J Med Genet* 68:240-241 (1997).
- Vaidyanathan G, Zalutsky MR: Fluorine-18-labeled [Nle<sup>4</sup>,D-Phe<sup>7</sup>]- $\alpha$ -MSH, an  $\alpha$ -melanocyte stimulating hormone analogue. *Nucl Med Biol* 24:171-178 (1997).
- Wong WS, Minchin RF: Binding and internalization of the melanocyte stimulating hormone receptor ligand [Nle<sup>4</sup>, D-Phe<sup>7</sup>]- $\alpha$ -MSH in B16 melanoma cells. *Int J Biochem Cell Biol* 28:1223-1232 (1996).
- Yagi H, Tokura Y, Furukawa F, Takigawa M: Vitiligo with raised inflammatory borders: Involvement of T cell immunity and keratinocytes expressing MHC class II and ICAM-1 molecules. *European J Dermatology* 7:19-22 (1997).
- Yu HS, Chang KL, Yu CL, Li HF, Wu MT, Wu CS: Alterations in IL-6, IL-8, GM-CSF, TNF- $\alpha$ , and IFN- $\gamma$  release by peripheral mononuclear cells in patients with active vitiligo. *J Invest Dermatol* 108:527-529 (1997).
- Zhu Y, Thomas P: Effects of somatolactin on melanosome aggregation in the melanophores of red drum (*Sciaenops ocellatus*) scales. *Gen Comp Endocrinol* 105:127-133 (1997).

## MELANOMA & METASTASIS

- Abramson DH, Servodidio CA: Metastatic choroidal melanoma to the contralateral orbit 40 years after enucleation. *Arch Ophthalmol* 115:134(1997).
- Akporiaye ET, Panelli MC: Functional class II antigen presentation pathway in metastatic melanoma cell lines - Commentary. *J Immunother* 19:398(1996).
- Arienti F, SuleSuso J, Belli F, Mascheroni L, Rivoltini L, Melani C, Maio M, Cascinelli N, Colombo MP, Parmiani G: Limited antitumor T cell response in melanoma patients vaccinated with interleukin-2 gene-transduced allogeneic melanoma cells. *Hum Gene Ther* 7:1955-1963 (1996).
- Ariyan S: The association between melanoma, lymphoma, and other primary neoplasms - In reply. *Arch Surg* 132:320(1997).
- ❖ Ariyan S, Poo WJ, Bologna J: Regional isolated perfusion of extremities for melanoma: A 20-year experience with drugs other than L-phenylalanine mustard. *Plast Reconstr Surg* 99:1023-1029 (1997).
- Austin DF, Reynolds P: Investigation of an excess of melanoma among employees of the Lawrence Livermore National Laboratory. *Am J Epidemiol* 145:524-531 (1997).
- Baade PD, Balanda KP, Stanton WR, Gillespie AM, Lowe JB: Community perceptions about the important signs of early melanoma. *J Am Acad Dermatol* 36:33-39 (1997).
- Bakker ABH, vanderBurg SH, Huijbens RJF, Drijfhout JW, Melief CJM, Adema GJ, Figdor CG: Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. *Int J Cancer* 70:302-309 (1997).
- Barnhill RL, Fine JA, Roush GC, Berwick M: Predicting five-year outcome for patients with cutaneous melanoma in a population-based study (Vol 78, pg 427, 1996). *Cancer* 79:423(1997).
- Basler GC, Fader DJ, Yahanda A, Sondak VK, Johnson TM: The utility of fine needle aspiration in the diagnosis of melanoma metastatic to lymph nodes. *J Am Acad Dermatol* 36:403-408 (1997).
- Baudler M, Duschl J, Winkler C, Scharfl M, Altschmied J: Activation of transcription of the melanoma inducing X<sup>mrk</sup> oncogene by a GC box element. *J Biol Chem* 272:131-137 (1997).
- Baudler M, Duschl J, Winkler C, Scharfl M, Altschmied J: Activation of transcription of the melanoma inducing X<sup>mrk</sup> oncogene by a GC box element (Vol 272, pg 131, 1997). *J Biol Chem* 272:7565(1997).
- Becher R, Korn WM, Prescher G: Use of fluorescence *in situ* hybridization and comparative genomic hybridization in the cytogenetic analysis of testicular germ cell tumors and uveal melanomas. *Cancer Genet Cytogenet* 93:22-28 (1997).
- Bellone M, Iezzi G, MartinFontecha A, Rivolta L, Manfredi AA, Protti MP, Freschi M, Dellabona P, Casorati G, Rugarli C: Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. *J Immunol* 158:783-789 (1997).
- Bender H, Grapow M, Schomburg A, Reinhold U, Biersack HJ: Effects of diagnostic application of monoclonal antibody on survival in melanoma patients. *Hybridoma* 16:65-68 (1997).

- Bentham G, Aase A: Incidence of malignant melanoma of the skin in Norway, 1955-1989: Associations with solar ultraviolet radiation, income and holidays abroad. *Int J Epidemiol* 25:1132-1138 (1996).
- Berg P, Lindelof B: Differences in malignant melanoma between children and adolescents : A 35-year epidemiological study. *Arch Dermatol* 133:295-297 (1997).
- Berger W, Hauptmann E, Elbling L, Vetterlein M, Kokoschka EM, Micksche M: Possible role of the multidrug resistance-associated protein (MRP) in chemoresistance of human melanoma cells. *Int J Cancer* 71:108-115 (1997).
- Berking C, Brady MS: Cutaneous melanoma in patients with sarcoma. *Cancer* 79:843-848 (1997).
- Blessing K: Malignant melanoma in stasis dermatitis. *Histopathology* 30:135-139 (1997).
- Blom DJR, Mooy CM, Luyten GPM, Kerkvliet S, Ouwerkerk I, Zwinderman AH, Schrier PI, Jager MJ: Inverse correlation between expression of HLA-B and c-myc in uveal melanoma. *J Pathol* 181:75-79 (1997).
- Blom DJR, Schuitmaker HJ, deWaardSiebinga I, Dubbelman TMAR, Jager MJ: Decreased expression of HLA class I on ocular melanoma cells following *in vitro* photodynamic therapy. *Cancer Lett* 112:239-243 (1997).
- Bloom MB, PerryLalley D, Robbins PF, Li Y, ElGamil M, Rosenberg SA, Yang JC: Identification of tyrosinase-related protein 2 as a tumor rejection antigen for the B16 melanoma. *J Exp Med* 185:453-459 (1997).
- Bodey B, Groger AM, Siegel SE, Kaiser HE: Nm23/Nucleoside diphosphate (NDP) kinase expression in human malignant melanomas: Significance and implications in tumor biology. *Anticancer Res* 17:505-511 (1997).
- Bodey B, Siegel SE, Luck JV, Kaiser HE: Immunophenotypic characterization of human primary and metastatic melanoma infiltrating leukocytes. *Anticancer Res* 16:3439-3446 (1996).
- Bono A, Bartoli C, Tessandri L, DelPrato I, Tragni G, Bucci A, Moglia D, Cascinelli N: *In situ* and very thin melanomas (<0.75 mm) are similarly and commonly recognizable. *Tumori* 82:600-602 (1996).
- Bortolotti U: Right atrial metastatic melanoma. *Ann Thorac Surg* 63:293(1997).
- Botev IN: Malignant melanoma in association with inflammatory skin metastasis. *J Am Acad Dermatol* 36:280(1997).
- Brady MS, Eckels DD, Ree SY, Schultheiss KE, Lee JS: MHC class II-mediated antigen presentation by melanoma cells. *J Immunother* 19:387-397 (1996).
- Brandwein MS, Rothstein A, Lawson W, Bodian C, Urken ML: Sinonasal melanoma: A clinicopathologic study of 25 cases and literature meta-analysis. *Arch Otolaryngol Head Neck Surg* 123:290-296 (1997).
- Buzaid AC, Ross MI, Balch CM, Soong SJ, McCarthy WH, Tinoco L, Mansfield P, Lee JE, Bedikian A, Eton O, Plager C, Papadopoulos N, Legha SS, Benjamin RS: Critical analysis of the current American Joint Committee on Cancer staging system for cutaneous melanoma and proposal of a new staging system. *J Clin Oncol* 15:1039-1051 (1997).
- ❖ Bystryn JC: Immunotherapy of melanoma with vaccines. *Eurocancer 96 - Compte Rendu du Ixe Congres* 267-268:-268 (1996).
- Chang SA, Lacaille VG, Guttoh DS, Androlewicz MJ: Binding and transport of melanoma-specific antigenic peptides by the transporter associated with antigen processing. *Mol Immunol* 33:1165-1169 (1996).
- Chen D, Guo JR, Gahl WA: rab GTPases expressed in human melanoma cells. *Bba Mol Cell Res* 1355:1-6 (1997).
- Chiarello SE: Every day is Melanoma Monday. *J Am Acad Dermatol* 35:649(1996).
- Cohen LM: Lentigo maligna and lentigo maligna melanoma - Reply. *J Am Acad Dermatol* 36:500(1997).
- Cook J, Zitelli JA: Treating patients with melanoma with interferon. *Arch Dermatol* 133:387(1997).
- Cook MG, Clarke TJ, Humphreys S, Fletcher A, McLaren KM, Smith NP, Stevens A, Theaker JM, Melia J: A nationwide survey of observer variation in the diagnosis of thin cutaneous malignant melanoma including the MIN terminology. *J Clin Pathol* 50:202-205 (1997).
- Cunningham CC, Leclerc N, Flanagan LA, Lu M, Janmey PA, Kosik KS: Microtubule-associated protein 2c reorganizes both microtubules and microfilaments into distinct cytological structures in an actin-binding protein-280-deficient melanoma cell line. *J Cell Biol* 136:845-857 (1997).
- Dallimore KJ: Lentigo maligna and lentigo maligna melanoma. *J Am Acad Dermatol* 36:500(1997).
- dePinieux G, Spatz A, Avril MF, Lasser P, Ducreux M, Bourhis J, Duvillard P: Primary anorectal melanoma. Nine cases. *Ann Pathol* 16:463-466 (1996).
- Dewhurst LO, Gee JW, Rennie IG, MacNeil S: Tamoxifen, 17  $\beta$ -oestradiol and the calmodulin antagonist J8 inhibit human melanoma cell invasion through fibronectin. *Br J Cancer* 75:860-868 (1997).
- Dubertret L: Physiopathology of malignant melanoma. *Eurocancer 96 - Compte Rendu du Ixe Congres* 263-264:-264 (1996).
- Dummer R, Boni R, Yue FY, Laine E, Burg G: Cytokines in the immune biology of melanoma. *Head and Neck Cancer - Advances in Basic Research* 1114 679-688:-688 (1996).
- Eedy DJ: Malignant melanoma in childhood. *Br J Dermatol* 136:137-138 (1997).
- Egan CA, Bradley RR, Logsdon VK, Summers BK, Hunter GR, Vanderhooft SL: Vulvar melanoma in childhood. *Arch Dermatol* 133:345-348 (1997).
- Egyhazi S, Margison GP, Hansson J, Ringborg U: Immunohistochemical examination of the expression of O-6-methylguanine-DNA methyltransferase in human melanoma metastases. *Eur J Cancer* 33:129-134 (1997).
- Ehara H, Takahashi Y, Saitoh A, Kawada M, Shimokawa K, Kanemura T: Clear cell melanoma of the renal pelvis presenting as a primary tumor. *J Urol* 157:634(1997).
- Eshima I: The role of plastic surgery in the treatment of malignant melanoma. *Surg Clin North Am* 76:1331(1996).
- Falus A, Laszlo V, Radvany Z, Hegyesi H, Kiss B, Bencsath M, Darvas Z: Histidine decarboxylase and intracellular histamine in melanoma cells and in a T cell line. *Inflamm Research* 46:S51-S52:S51-S52 (1997).

- Fetsch PA, Cormier J, Hijazi YM: Immunocytochemical detection of MART-1 in fresh and paraffin-embedded malignant melanomas. *J Immunother* 20:60-64 (1997).
- Fine SL: The accuracy of diagnosis of posterior uveal melanoma - Reply. *Arch Ophthalmol* 115:433-434 (1997).
- Fleischmann CM, Wu TY, Fleischmann WR: B16 melanoma cells exposed *in vitro* to long-term IFN- $\alpha$  treatment (B16  $\alpha$  cells) as activators of tumor immunity in mice. *J Interferon Cytokine Res* 17:37-43 (1997).
- Folberg R: Reassessment of the PAS patterns in uveal melanoma - Discussion. *Br J Ophthalmol* 81:247-248 (1997).
- Foss AJE, Alexander RA, Hungerford JL, Harris AL, Lightman S: Reassessment of the PAS patterns in uveal melanoma. *Br J Ophthalmol* 81:240-246 (1997).
- Freije JMP, Lawrence JA, Hollingshead MG, DeLaRosa A, Narayanan V, Grever M, Sausville EA, Paul K, Steeg PS: Identification of compounds with preferential inhibitory activity against low-Nm23-expressing human breast carcinoma and melanoma cell lines. *Nature Med* 3:395-401 (1997).
- Fritsch C, Abels C, Goetz AE, Stahl W, Bolsen K, Ruzicka T, Goerz G, Sies H: Porphyrins preferentially accumulate in a melanoma following intravenous injection of 5-aminolevulinic acid. *Biol Chem* 378:51-57 (1997).
- Geara FB, Ang KK: Radiation therapy for malignant melanoma. *Surg Clin North Am* 76:1383(1996).
- Ginobbi P, Geiser TA, Ombres D, Citro G: Folic acid polylysine carrier improves efficacy of c-myc antisense oligodeoxynucleotides on human melanoma (M14) cells. *Anticancer Res* 17:29-35 (1997).
- Giraud P, Bachaud JM, Teissie J: Effects of electrochemotherapy on cutaneous metastases of human malignant melanoma. *Int J Radiat Oncol Biol Phys* 36:1285(1996).
- Goldbrunner RH, Haugland HK, Klein CE, Kerkau S, Roosen K, Tonn JC: ECM dependent and integrin mediated tumor cell migration of human glioma and melanoma cell lines under serum-free conditions. *Anticancer Res* 16:3679-3687 (1996).
- Gorelik E, Xu F, Henion T, Anaraki F, Galili U: Reduction of metastatic properties of BL6 melanoma cells expressing terminal fucose  $\alpha$  1-2-galactose after  $\alpha$  1,2-fucosyltransferase cDNA transfection. *Cancer Res* 57:332-336 (1997).
- Gorospe M, Cirielli C, Wang XT, Seth P, Capogrossi MC, Holbrook NJ: p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. *Oncogene* 14:929-935 (1997).
- Gracely EJ: The association between melanoma, lymphoma, and other primary neoplasms. *Arch Surg* 132:320(1997).
- Hansen C, Ablett E, Green A, Sturm RA, Dunn IS, Fairlie DP, West ML, Parsons PG: Biphasic response of the metallothionein promoter to ultraviolet radiation in human melanoma cells. *Photochem Photobiol* 65:550-555 (1997).
- Hansson J, Martenhed G, Egyhazi S, Tani E, Platz A: Analysis of O-6 methylguanine-DNA methyltransferase mRNA in fine needle biopsies from human melanoma metastases by reverse transcription and polymerase chain reaction. *Eur J Cancer* 32A:2319-2326 (1996).
- Hauschild A, Christophers E: Cytokines in melanoma: Clinical application. *Head and Neck Cancer - Advances in Basic Research* 1114 689-697:-697 (1996).
- Heasley DD, Toda S, Mihm MC: Pathology of malignant melanoma. *Surg Clin North Am* 76:1223(1996).
- Hishii M, Andrews D, Boyle LA, Wong JT, Pandolfi F, vandenElsen PJ, Kurnick JT: *In vivo* accumulation of the same anti-melanoma T cell clone in two different metastatic sites. *Proc Natl Acad Sci USA* 94:1378-1383 (1997).
- Hornstein MD, Thomas PP, Sober AJ, Wyshak G, Albright NL, Frisch RE: Association between endometriosis, dysplastic naevi and history of melanoma in women of reproductive age. *Hum Reprod* 12:143-145 (1997).
- ❖ Houghton AN, Meyers ML, Chapman PB: Medical treatment of metastatic melanoma. *Surg Clin North Am* 76:1343(1996).
- Huang TSW, Rauth S, DasGupta TK: Overexpression of EGF receptor is associated with spontaneous metastases of a human melanoma cell line in nude mice. *Anticancer Res* 16:3557-3563 (1996).
- Huang X, Soong SJ, McCarthy WH, Urist MM, Balch CM: Classification of localized melanoma by the exponential survival trees method. *Cancer* 79:1122-1128 (1997).
- Jansen B, SchlagbauerWadl H, Eichler HG, Wolff K, vanElsas A, Schrier PI, Pehamberger H: Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis. *Cancer Res* 57:362-365 (1997).
- Johansson BR, Nannmark U: Ultrastructure of interactions between activated murine natural killer cells and melanoma cells in an extracellular matrix (Matrigel(R)) environment. *Nat Immun* 15:98-106 (1996).
- JourneedeKorver JG, Oosterhuis JA, deWolffRouendaal D, Kemme H: Histopathological findings in human choroidal melanomas after transpupillary thermotherapy. *Br J Ophthalmol* 81:234-239 (1997).
- ❖ Kageshita T, Naruse T, Hirai S, Horikoshi T, Nakagawa H, Tamaki K, Hayashibe K, Ichihashi M, Nakayama J, Hori Y, Ozawa A, Miyahara M, Ohkido M, Inoko H, Ono T: HLA class I antigens in Japanese patients with melanoma. *J Immunother* 19:428-432 (1996).
- Kang XQ, Robbins PF, Fitzgerald EB, Wang RF, Rosenberg SA, Kawakami Y: Induction of melanoma reactive T cells by stimulator cells expressing melanoma epitope-major histocompatibility complex class I fusion proteins. *Cancer Res* 57:202-205 (1997).
- Kanno J, Wakikawa A, Utsuyama M, Hirokawa K: Effect of restraint stress on immune system and experimental B16 melanoma metastasis in aged mice. *Mech Ageing Dev* 93:107-117 (1997).
- Karakousis CP: Surgical treatment of malignant melanoma. *Surg Clin North Am* 76:1299(1996).



- Karasawa K, Sugiura N, Hori Y, Suzuki S, Onaya J, Sakurai K, Kimata K: Inhibition of experimental metastasis and cell adhesion of murine melanoma cells by chondroitin sulfate-derivatized lipid, a neoproteoglycan with anti-cell adhesion activity. *Clin Exp Metastasis* 15:83-93 (1997).
- Kato T, Tabata N, Suetake T, Tagami H: Non-pigmented nodular plantar melanoma in 12 Japanese patients. *Br J Dermatol* 136:207-211 (1997).
- ❖ Kawakami Y, Battles JK, Kobayashi T, Ennis W, Wang X, Tupesis JP, Marincola FM, Robbins PF, Hearing VJ, Gonda MA, Rosenberg SA: Production of recombinant MART-1 proteins and specific antiMART-1 polyclonal and monoclonal antibodies: Use in the characterization of the human melanoma antigen MART-1. *J Immunol Methods* 202:13-25 (1997).
- Kirkwood J, Greenway H: Treating patients with melanoma with interferon - Reply. *Arch Dermatol* 133:387-389 (1997).
- Kirkwood JM, Bryant J, Schiller JH, Oken MM, Borden EC, Whiteside TL: Immunomodulatory function of interferon- $\gamma$  in patients with metastatic melanoma: Results of a phase II-B trial in subjects with metastatic melanoma, ECOG study E 4987. *J Immunother* 20:146-157 (1997).
- Klatzmann D: Metastatic malignant melanoma and glioblastoma: Gene therapy by transfer of the thymidine kinase gene of Herpes simplex virus type-1 followed by ganciclovir treatment. *Eurocancer 96 - Compte Rendu du Ixe Congres* 79-80:80 (1996).
- Kneier AW: The psychological challenges facing melanoma patients. *Surg Clin North Am* 76:1413(1996).
- Kobayashi M, Pollard RB, Suzuki F: Inhibition of pulmonary metastasis by Z-100, an immunomodulatory lipid-arabinomannan extracted from *Mycobacterium tuberculosis*, in mice inoculated with B16 melanoma. *Anti Cancer Drug* 8:156-163 (1997).
- Korabiowska M, Brinckmann U, Kellner S, Brinck U, Stachura J, Schauer A: Differences of ploidy status in progression of head and neck melanomas. *Int J Oncol* 10:381-385 (1997).
- Krementz ET, Sutherland CM, Muchmore JH: Isolated hyperthermia chemotherapy perfusion for limb melanoma. *Surg Clin North Am* 76:1313(1996).
- Kwapiszewski BR, Savitt ML: Conjunctival metastasis from a cutaneous melanoma as the initial sign of dissemination. *Am J Ophthalmol* 123:266-268 (1997).
- Labarriere N, Diez E, Pandolfino MC, Viret C, Guilloux Y, LeGuiner S, Fonteneau JF, Dreno B, Jotereau F: Optimal T cell activation by melanoma cells depends on a minimal level of antigen transcription. *J Immunol* 158:1238-1245 (1997).
- ❖ Langley RGB, Bailey EM, Sober AJ: Acute cholecystitis from metastatic melanoma to the gall-bladder in a patient with a low-risk melanoma. *Br J Dermatol* 136:279-282 (1997).
- Ledda F, Bravo AI, Adris S, Bover L, Mordoh J, Podhajcer OL: The expression of the secreted protein acidic and rich in cysteine (SPARC) is associated with the neoplastic progression of human melanoma. *J Invest Dermatol* 108:210-214 (1997).
- Ledda MF, Adris S, Bravo AI, Kairiyama C, Bover L, Chernajovsky Y, Mordoh J, Podhajcer OL: Suppression of SPARC expression by antisense RNA abrogates the tumorigenicity of human melanoma cells. *Nature Med* 3:171-176 (1997).
- Lenisa L, Tragni G, Belli F, Gallino G, Mascheroni L, Cascinelli N: Solitary melanoma metastasis of the kidney: A case report. *Tumori* 82:614-615 (1996).
- Leong SPL: Immunotherapy of malignant melanoma. *Surg Clin North Am* 76:1355(1996).
- Leong SPL, Liliental J, Krams SM, Zhou YM, Granberry ME, Martinez OM: T cell receptor usage by cytotoxic T lymphocytes against autologous human melanoma. *Anticancer Res* 16:3355-3361 (1996).
- Lin JJ, Jiang HP, Fisher PB: Characterization of a novel melanoma differentiation- associated gene, mda-9, that is down-regulated during terminal cell differentiation. *Mol Cell Differ* 4:317-333 (1996).
- Liu TP, Soong SJ: Epidemiology of malignant melanoma. *Surg Clin North Am* 76:1205(1996).
- Livingston P, Zhang SL, Adluri S, Yao TJ, Graeber L, Ragupathi G, Helling F, Fleisher M: Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies. *Cancer Immunol Immunother* 43:324-330 (1997).
- ❖ Loir B, Bouchard B, Morandini R, DelMarmol V, Deraemaeker R, GarciaBorrón JC, Ghanem G: Immunoreactive  $\alpha$ -melanotropin as an autocrine effector in human melanoma cells. *Eur J Biochem* 244:923-930 (1997).
- Lugassy C, Eyden BP, Christensen L, Escande JP: Angio-tumoral complex in human malignant melanoma characterised by free laminin: Ultrastructural and immunohistochemical observations. *J Submicrosc Cytol Pathol* 29:19-28 (1997).
- Lyng H, Tufto I, Skretting A, Rofstad EK: Proton relaxation times and interstitial fluid pressure in human melanoma xenografts. *Br J Cancer* 75:180-183 (1997).
- Manoukian S, Briscioli V, Lalatta F: Malignant melanoma and Charcot-Marie-Tooth disease: A further case. *Am J Med Genet* 68:242(1997).
- Marchand M, Brichard V, Weynants P, Boon T: Immunotherapy of melanoma using specific tumor antigens recognized by cytolytic T-lymphocytes. *Eurocancer 96 - Compte Rendu du Ixe Congres* 269-270:270 (1996).
- Margo CE: The accuracy of diagnosis of posterior uveal melanoma. *Arch Ophthalmol* 115:432-433 (1997).
- Martin A, Luo ZJ, Cunningham C, Ohta Y, Hartwig J, Stossel TP, Kyriakis JM, Avruch J: Actin-binding protein-280 binds the stress-activated protein kinase (SAPK) activator SEK-1 and is required for tumor necrosis factor- $\alpha$  activation of SAPK in melanoma cells. *J Biol Chem* 272:2620-2628 (1997).
- Matsumura Y, Yamagishi N, Miyakoshi J, Imamura S, Takebe H: Increase in radiation sensitivity of human malignant melanoma cells by expression of wild-type p16 gene. *Cancer Lett* 115:91-96 (1997).

- McClay EF, McClay MET, Jones JA, Winski PJ, Christen RD, Howell SB, Hall PD: A Phase I and pharmacokinetic study of high dose tamoxifen and weekly cisplatin in patients with metastatic melanoma. *Cancer* 79:1037-1043 (1997).
- McKay AJ: Surgical management of malignant melanoma. *Br J Surg* 84:5-7 (1997).
- McLean IW, Sibug ME, Becker RL, McCurdy JB: Uveal melanoma: The importance of large nucleoli in predicting patient outcome - An automated image analysis study. *Cancer* 79:982-988 (1997).
- Mickiewicz E: Immunotherapy in melanoma and renal tumors. *Medicina Buenos Aires* 56:89-91:89-91 (1996).
- Moller P, Schadendorf D: Somatic gene therapy and its implications in melanoma treatment. *Arch Dermatol Res* 289:71-77 (1997).
- Mooi WJ: Diagnosis of thin melanoma. *J Clin Pathol* 50:179-180 (1997).
- Moral A, Palou J, Lafuente A, Molina R, Piulachs J, Castel T, Trias M, Mascaro JM, Vilalta A, Ballesta A, Molina T, Estivill X, Estape J: Immunohistochemical study of  $\alpha$ ,  $\mu$  and  $\pi$  class glutathione S transferase expression in malignant melanoma. *Br J Dermatol* 136:345-350 (1997).
- Mordoh J: Melanoma: Model and opportunities for immunologic intervention. *Medicina Buenos Aires* 56:85-88:85-88 (1996).
- MoreauAubry A, Fonteneau JF, Labarriere N, Jotereau F, Houssaint E, Breathnach R: Identification of a gp100 epitope recognized by HLA-A3 restricted melanoma infiltrating lymphocytes. *Int J Oncol* 10:841-846 (1997).
- Morgan CD, Measel JW, Amoss MS, Rao A, Greene JF: Immunophenotypic characterization of tumor infiltrating lymphocytes and peripheral blood lymphocytes isolated from melanomatous and non-melanomatous Sinclair miniature swine. *Vet Immunol Immunopathol* 55:189-203 (1996).
- Moudgil GC, Singal DP: Halothane and isoflurane enhance melanoma tumour metastasis in mice. *Can J Anaesth* 44:90-94 (1997).
- Nabel GJ, Gordon D, Bishop DK, Nickoloff BJ, Yang ZY, Aruga A, Cameron MJ, Nabel EG, Chang AE: Immune response in human melanoma after transfer of an allogeneic class I major histocompatibility complex gene with DNA-liposome complexes. *Proc Natl Acad Sci USA* 93:15388-15393 (1996).
- Nakano T, Matsui T, Ota T: Benzyl- $\alpha$ -GalNAc inhibits sialylation of O-glycosidic sugar chains on CD44 and enhances experimental metastatic capacity in B16BL6 melanoma cells. *Anticancer Res* 16:3577-3584 (1996).
- Nathanson SD, Avery M, Anaya P, Sarantou T, Hetzel FW: Lymphatic diameters and radionuclide clearance in a murine melanoma model. *Arch Surg* 132:311-315 (1997).
- Nelson MA, Thompson FH, Emerson J, Aickin M, Adair L, Trent JM, Leong SPL, Taetle R: Clinical implications of cytogenetic abnormalities in melanoma. *Surg Clin North Am* 76:1257(1996).
- Nicholl C, Mohammed A, Hull WE, Bubeck B, Eisenhut M: Pharmacokinetics of iodine-123-IMBA for melanoma imaging. *J Nucl Med* 38:127-133 (1997).
- Nordenberg J, Goldwasser I, ZorefShani E, Beery E, Sidi Y: Inhibition of B16 melanoma cell proliferation and alterations in p21 ras expression induced by interceptors of signal transduction pathways. *Isr J Med Sci* 32:1153-1157 (1996).
- ❖ Okun MR: Silhouette symmetry: An unsupportable histologic criterion for distinguishing Spitz nevi and compound nevi from malignant melanoma. *Arch Pathol Lab Med* 121:48-53 (1997).
- Ollivaud L: What's new in the area of melanoma diagnostics and therapeutics? *Eurocancer 96 - Compte Rendu du Ixe Congres* 265-266:-266 (1996).
- Ottino P, Duncan JR: Effect of vitamin E and indomethacin treatment on adenylate cyclase activity, PGE(2) and cAMP levels in murine melanoma cells. *Prostaglandin Leuk Essent Fatty* 56:143-149 (1997).
- Ottino P, Duncan JR: Effect of vitamin E succinate on free radical formation, lipid peroxidation levels and cyclooxygenase activity in murine melanoma cells. *Nutr Res* 17:661-676 (1997).
- Pansky A, Peng F, Eberhard M, Baselgia L, Siegrist W, Baumann JB, Eberle AN, Beglinger C, Hildebrand P: Identification of functional GRP-preferring bombesin receptors on human melanoma cells. *Eur J Clin Invest* 27:69-76 (1997).
- Parry D, Papon J, Moins N, Moreau MF, Morin C: A boronated benzamide as melanoma-seeking agent. *Bioorg Medicinal Chem Letter* 7:361-364 (1997).
- ❖ Pereira S, VanBelle P, Elder D, Maruyama H, Jacob L, Sivanandham M, Wallack M, Siegel D, Herlyn D: Combinatorial antibodies against human malignant melanoma. *Hybridoma* 16:11-16 (1997).
- Piepkorn M: Revising the practice of melanoma margin resections - Reply. *Arch Dermatol* 133:104-105 (1997).
- PineiroSanchez ML, Goldstein LA, Dodt J, Howard L, Yeh Y, Chen WT: Identification of the 170-kDa melanoma membrane-bound gelatinase (seprase) as a serine integral membrane protease. *J Biol Chem* 272:7595-7601 (1997).
- Planting AST, deWit R, vanderBurg MEL, Stoter G, Verweij J: Phase II study of a closely spaced ifosfamide-cisplatin schedule with the addition of G-CSF in advanced non-small- cell lung cancer and malignant melanoma. *Ann Oncol* 7:1080-1082 (1996).
- Radford KJ, Thorne RF, Hersey P: Regulation of tumor cell motility and migration by CD63 in a human melanoma cell line. *J Immunol* 158:3353-3358 (1997).
- Radhi JM: Urethral malignant melanoma closely mimicking urothelial carcinoma. *J Clin Pathol* 50:250-252 (1997).
- Rankin EM: Retroviral transfer of GM-CSF in melanoma: Use as a vaccine in patients with advanced disease. *Eurocancer 96 - Compte Rendu du Ixe Congres* 77-78:-78 (1996).
- Reinhold U, Hartl C, Hering R, Hoeft A, Kreysel HW: Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma. *Lancet* 349:540-541 (1997).

- Reinhold U, LudtkeHandjery HC, Schnautz S, Kreysel HW, Abken H: The analysis of tyrosinase-specific mRNA in blood samples of melanoma patients by RT-PCR is not a useful test for metastatic tumor progression. *J Invest Dermatol* 108:166-169 (1997).
- Reintgen D, Balch CM, Kirkwood J, Ross M: Recent advances in the care of the patient with malignant melanoma. *Ann Surg* 225:1-14 (1997).
- Reintgen D, King J, Cox C: Computer database for melanoma registry: A clinical management and research tool to monitor outcomes and ensure continuous quality improvement. *Surg Clin North Am* 76:1273(1996).
- ❖ Rieber MS, Rieber M: Sensitization to DNA damage by okadaic acid of bromodeoxyuridine involves unequal effects on melanoma cell adhesion and differentiation. *DNA Cell Biol* 16:121-125 (1997).
- Ross MI: Staging evaluation and surveillance for melanoma patients in a fiscally restrictive medical environment: A commentary. *Surg Clin North Am* 76:1423(1996).
- Rubinfeld B, Robbins P, ElGamil M, Albert I, Porfiri E, Polakis P: Stabilization of  $\beta$ -catenin by genetic defects in melanoma cell lines. *Science* 275:1790-1792 (1997).
- RuizMaldonado R, OrozcoCovarrubias MD: Malignant melanoma in children: A review. *Arch Dermatol* 133:363-371 (1997).
- Safarians S, Rivera SP, Sternlicht MD, Naeim F, Barsky SH: Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression. *Am J Pathol* 150:949-962 (1997).
- Sagebiel RW: The multidisciplinary melanoma center. *Surg Clin North Am* 76:1433(1996).
- Sanders CJG: Revising the practice of melanoma margin resections. *Arch Dermatol* 133:103-104 (1997).
- Sankaran N: A call for stepped-up melanoma screening. *Ann Intern Med* 126:160-161 (1997).
- Sarantou T, Chi DDJ, Garrison DA, Conrad AJ, Schmid P, Morton DL, Hoon DSB: Melanoma-associated antigens as messenger RNA detection markers for melanoma. *Cancer Res* 57:1371-1376 (1997).
- Sato T, Babazono A, Shields JA, Shields CL, DePotter P, Mastrangelo MJ: Time to systemic metastases in patients with posterior uveal melanoma. *Cancer Invest* 15:98-105 (1997).
- Schachter J, Klein T, Klein B, Adler A: HLA class I and advanced melanoma in Israeli Jews. *Int J Oncol* 10:645-648 (1997).
- Schneeberger A, Schreiber S, Zatloukal K, Birnstiel ML, Stingl G: Cancer vaccines in melanoma: Studies in man and in experimental animals. *Head and Neck Cancer - Advances in Basic Research* 1114 699-701:701 (1996).
- Schwabe M, Deryugina EI, Bosco MC, Gusella GL, Reinisch W, Kung HF, Bourdon MA: IL-6 signals inhibition of cell adhesion in melanoma A375- C6. *Anticancer Res* 16:3363-3370 (1996).
- Schwartz LH, Ferrand R, Boelle PY, Maylin C, DHermies F, Virmont J: Lack of correlation between the location of choroidal melanoma and ultraviolet-radiation dose distribution. *Radiat Res* 147:451-456 (1997).
- Scott CT, Holland GN, Glasgow BJ: Cavitation in ciliary body melanoma. *Am J Ophthalmol* 123:269-271 (1997).
- Seigler HF: Advances in the care of the patient with malignant melanoma. *Ann Surg* 225:15-16 (1997).
- Sensi M, Farina C, Maccalli C, Lupetti R, Nicolini G, Anichini A, Parmiani G, Berd D: Clonal expansion of T lymphocytes in human melanoma metastases after treatment with a hapten-modified autologous tumor vaccine. *J Clin Invest* 99:710-717 (1997).
- Seung SK, Shu HKG, McDermott MW, Sneed PK, Larson DA: Stereotactic radiosurgery for malignant melanoma to the brain. *Surg Clin North Am* 76:1399(1996).
- Sollner W, ZinggSchir M, Rumpold G, Fritsch P: Attitude toward alternative therapy, compliance with standard treatment, and need for emotional support in patients with melanoma. *Arch Dermatol* 133:316-321 (1997).
- Stahl A, Mueller BM: Melanoma cell migration on vitronectin: Regulation by components of the plasminogen activation system. *Int J Cancer* 71:116-122 (1997).
- Stopeck AT, Hersh EM, Akporiaye ET, Harris DT, Grogan T, Unger E, Warneke J, Schluter SF, Stahl S: Phase I study of direct gene transfer of an allogeneic histocompatibility antigen, HLA-B7, in patients with metastatic melanoma. *J Clin Oncol* 15:341-349 (1997).
- Straten PT, Kirkin AF, Seremet T, Zeuthen J: Expression of transporter associated with antigen processing 1 and 2 (TAP1/2) in malignant melanoma cell lines. *Int J Cancer* 70:582-586 (1997).
- Swetter SM: Malignant melanoma from the dermatologic perspective. *Surg Clin North Am* 76:1287(1996).
- Talve LAI, Collan YUI, Ekfors TO: Primary malignant melanoma of the skin - Relationships of nuclear DNA content, nuclear morphometric variables, Clark level and tumor thickness. *Anal Quant Cytol Histol* 19:62-74 (1997).
- Tamir G, Milo Y, Rothen A, Sulkes J, Hauben DJ: Cutaneous malignant melanoma in young adults under age 30. *Isr J Med Sci* 32:1290-1296 (1996).
- Tanabe KK: Lymphatic mapping and epitrochlear lymph node dissection for melanoma. *Surgery* 121:102-104 (1997).
- Tani M, ShindoOkada N, Hashimoto Y, Shiroishi T, Takenoshita S, Nagamachi Y, Yokota J: Isolation of a novel Sry-related gene that is expressed in high-metastatic K-1735 murine melanoma cells. *Genomics* 39:30-37 (1997).
- Thomas WD, Smith MJ, Si Z, Hersey P: Expression of the co-stimulatory molecule CD40 on melanoma cells. *Int J Cancer* 68:795-801 (1996).
- Trent JM, Bittner MH, Zhang J, Wiltshire R, Ray M, Su Y, Gracia E, Meltzer P, DeRisi J, Penland L, Brown P: Use of microgenomic technology for analysis of alterations in DNA copy number and gene expression in malignant melanoma. *Clin Exp Immunol* 107:33-40:33-40 (1997).
- Tronnier M: UV-light in the pathogenesis of human malignant melanoma. *Head and Neck Cancer - Advances in Basic Research* 1114 659-663:663 (1996).

- Tsai V, Southwood S, Sidney J, Sakaguchi K, Kawakami Y, Appella E, Sette A, Celis E: Identification of subdominant CTL epitopes of the GP100 melanoma-associated tumor antigen by primary *in vitro* immunization with peptide-pulsed dendritic cells. *J Immunol* 158:1796-1802 (1997).
- Tsomides TJ, Reilly EB, Eisen HN: Anti-melanoma cytotoxic T lymphocytes (CTL) recognize numerous antigenic peptides having 'self' sequences: Autoimmune nature of the anti-melanoma CTL response. *Int Immunol* 9:327-338 (1997).
- Valmori D, Lienard D, Waanders G, Rimoldi D, Cerottini JC, Romero P: Analysis of MAGE-3-specific cytolytic T lymphocytes in human leukocyte antigen-A2 melanoma patients. *Cancer Res* 57:735-741 (1997).
- vanderLindeSipman JS, deWit MML, vanGarderen E, Molenbeek RF, vanderVeldeZimmermann D, deWeger RA: Cutaneous malignant melanomas in 57 cats: Identification of (amelanotic) signet-ring and balloon cell types and verification of their origin by immunohistochemistry, electron microscopy, and *in situ* hybridization. *Vet Pathol* 34:31-38 (1997).
- vanGroningen JJM, Egmond MR, Bloemers HPJ, Swart GWM: *nmd*, a novel gene differentially expressed in human melanoma cell lines, encodes a new atypical member of the enzyme family of lipases. *FEBS Lett* 404:82-86 (1997).
- Vlaykova T, Jekunen AP, Kesomaa M, Kairemo KJA, Pyrhonen S, Wasenius VM: Increased thymidylate synthase gene expression in metastatic melanoma. *Oncology* 54:146-152 (1997).
- Vogt T, Zipperer KH, Vogt A, Holzel D, Landthaler M, Stolz W: p53-protein and Ki-67-antigen expression are both reliable biomarkers of prognosis in thick stage I nodular melanomas of the skin. *Histopathology* 30:57-63 (1997).
- Wagner SN: Cellular immune response against malignant melanoma. *Head and Neck Cancer - Advances in Basic Research* 1114 671-677:-677 (1996).
- Wan T, Cao XT, Ju DW, Aces B: *In vivo* gene therapy of murine melanoma mediated by recombinant vaccinia virus encoding human IL-2 gene. *Int J Oncol* 10:703-708 (1997).
- Weinstock MA: Resection margins in primary cutaneous melanoma. *Arch Dermatol* 133:103(1997).
- Wirnsberger GH, Kleinert R, Langmann G, Fuchs U: Tumor cell markers in uveal melanoma: An immunohistochemical study. *Int J Oncol* 10:793-799 (1997).
- Zemskov SV, Susak YM, Todor IN, Khasanova LT, Mosienko VS: Antimetastatic effect of Ukrain and its influence on the oxygen and energy metabolism of mice with melanoma B-16. *Exp Oncol* 18:405-408 (1996).
- Zhai YF, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA: Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. *J Immunother* 20:15-25 (1997).

## MSH, POMC, GROWTH FACTORS & RECEPTORS

- Amemiya Y, Takahashi A, Dores RM, Kawauchi H: Sturgeon proopiomelanocortin has a remnant of  $\gamma$ -melanotropin. *Biochem Biophys Res Commun* 230:452-456 (1997).
- Baumann JB, Bagutti C, Siegrist W, Christen E, Zumsteg U, Eberle AN: MSH receptors and the response of human A375 melanoma cells to interleukin-1  $\beta$ . *J Recept Signal Transduct Res* 17:199-210 (1997).
- Bhardwaj R, Becher E, Mahnke K, Hartmeyer M, Schwarz T, Scholzen T, Luger TA: Evidence for the differential expression of the functional  $\alpha$ -melanocyte-stimulating hormone receptor MC-1 human monocytes. *J Immunol* 158:3378-3384 (1997).
- Bhardwaj R, Blanchard J: *In vitro* evaluation of poly(D,L-lactide-co-glycolide) polymer-based implants containing the  $\alpha$ -melanocyte stimulating hormone analog, Melanotan-I. *J Control Release* 45:49-55 (1997).
- Chiao H, Kohda Y, McLeroy P, Craig L, Housini I, Star RA:  $\alpha$ -Melanocyte-stimulating hormone protects against renal injury after ischemia in mice and rats. *J Clin Invest* 99:1165-1172 (1997).
- deAguilar JLG, Malagon MM, VazquezMartinez RM, Lihmann I, Tonon MC, Vaudry H, GraciaNavarro F: Two frog melanotrope cell subpopulations exhibiting distinct biochemical and physiological patterns in basal conditions and under thyrotropin-releasing hormone stimulation. *Endocrinology* 138:970-977 (1997).
- DegliEsposti MA, DavisSmith T, Din WS, Smolak PJ, Goodwin RG, Smith CA: Activation of the lymphotoxin  $\beta$  receptor by cross-linking induces chemokine production and growth arrest in A375 melanoma cells. *J Immunol* 158:1756-1762 (1997).
- ❖ Dranoff G, Soiffer R, Lynch T, Mihm M, Jung K, Kolesar K, Liebster L, Duda R, Mentzer S, Singer S, Tanabe K, Johnson R, Sober A, Bhan A, Clift S, Cohen L, Parry G, Rokovich J, Richards L, Drayer J, Berns A, Mulligan RC: A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor. *Hum Gene Ther* 8:111-123 (1997).
- Dubocovich ML, Masana MI, Iacob S, Sauri DM: Melatonin receptor antagonists that differentiate between the human Mel(1a), and Mel(1b) recombinant subtypes are used to assess the pharmacological profile of the rabbit retina ML(1) presynaptic heteroreceptor. *Naunyn Schmied Arch Pharmacol* 355:365-375 (1997).
- DuBois JS, Trehu EG, Mier JW, Shapiro L, Epstein M, Klemptner M, Dinarello C, Kappler K, Ronayne L, Rand W, Atkins MB: Randomized placebo-controlled clinical trial of high-dose interleukin-2 in combination with a soluble p75 tumor necrosis factor receptor immunoglobulin G chimera in patients with advanced melanoma and renal cell carcinoma. *J Clin Oncol* 15:1052-1062 (1997).
- ❖ Ermak G, Slominski A: Production of POMC, CRH-R1, MC1, and MC2 receptor mRNA and expression of tyrosinase gene in relation to hair cycle and dexamethasone treatment in the C57BL/6 mouse skin. *J Invest Dermatol* 108:160-165 (1997).

- Godden JL, Edward M, Grant AW, MacKie RM: Partial characterisation of human melanoma cell-derived factors that stimulate fibroblast glycosaminoglycan synthesis. *Pathobiology* 64:262-268 (1996).
- ❖ Hadley ME, Hrubby VJ, Jiang JW, Sharma SD, Fink JL, Haskell-Luevano C, Bentley DL, AlObeidi F, Sawyer TK: Melanocortin receptors: Identification and characterization by melanotropic peptide agonists and antagonists. *Pigm Cell Res* 9:213-234 (1996).
  - ❖ Huszar D, Lynch CA, Fairchild-Huntress V, Dunmore JH, Fang Q, Berkemeier LR, Gu W, Kesterson RA, Boston BA, Cone RD, Smith FJ, Campfield LA, Burn P, Lee F: Targeted disruption of the melanocortin-4 receptor results in obesity in mice. *Cell* 88:131-141 (1997).
- Keller ET, Pugh TD, Sun WH, Ershler WB: Evaluation of ovariectomy and dehydroepiandrosterone sulfate administration on interleukin-6 levels and B16 melanoma growth in mice. *Age* 19:75-81 (1996).
- Kettelhack C, Hohenberger P, Schlag PM: Isolated hyperthermic limb perfusion with melphalan and tumour necrosis factor in malignant melanoma. *Dtsch Med Wochenschr* 122:177-181 (1997).
- Kiefer LL, Ittoop ORR, Bunce K, Truesdale AT, Willard DH, Nichols JS, Blanchard SG, Mountjoy K, Chen WJ, Wilkison WO: Mutations in the carboxyl terminus of the agouti protein decrease agouti inhibition of ligand binding to the melanocortin receptors. *Biochemistry* 36:2084-2090 (1997).
- Kim JH, Kiefer LL, Woychik RP, Wilkison WO, Truesdale A, Ittoop O, Willard D, Nichols J, Zemel MB: Agouti regulation of intracellular calcium: Role of melanocortin receptors. *Amer J Physiol Endocrinol Metab* 35:E379-E384 (1997).
- Kim JH, Mynatt RL, Moore JW, Woychik RP, Moustaid N, Zemel MB: The effects of calcium channel blockade on agouti-induced obesity. *FASEB J* 10:1646-1652 (1996).
- Kim Y, Carr JA: Alterations in brain and plasma concentrations of  $\alpha$ -melanocyte-stimulating hormone during habituation of prey-catching behavior in toads. *Brain Behav Evol* 49:149-161 (1997).
- Lipton JM, Catania A: Anti-inflammatory actions of the neuroimmunomodulator  $\alpha$ -MSH. *Immunol Today* 18:140-145 (1997).
- Lissoni P, Brivio O, Brivio F, Barni S, Tancini G, Crippa D, Meregalli S: Adjuvant therapy with the pineal hormone melatonin in patients with lymph node relapse due to malignant melanoma. *J Pineal Res* 21:239-242 (1996).
- Masback A, Wester Dahl J, Ingvar C, Olsson H, Jonsson N: Cutaneous malignant melanoma in southern Sweden 1965, 1975, and 1985: Prognostic factors and histologic correlations. *Cancer* 79:275-283 (1997).
- Maurer M, Handjiski B, Paus R: Hair growth modulation by topical immunophilin ligands: Induction of anagen, inhibition of massive catagen development, and relative protection from chemotherapy-induced alopecia. *Am J Pathol* 150:1433-1441 (1997).
- Nguyen TD, Smith MJ, Hersey P: Contrasting effects of T cell growth factors on T cell responses to melanoma *in vitro*. *Cancer Immunol Immunother* 43:345-354 (1997).
- Ota T, Maeda M, Matsui T, Kohno H, Tanino M, Odashima S: Inhibition of metastasis by a dialysable factor in fetal bovine serum in B16 melanoma cells. *Cancer Lett* 110:201-205 (1996).
- Pittack C, Grunwald GB, Reh TA: Fibroblast growth factors are necessary for neural retina but not pigmented epithelium differentiation in chick embryos. *Development* 124:805-816 (1997).
- Rajaratnam K, Kay CM, Dewald B, Wolf M, Baggolini M, Clark-Lewis I, Sykes BD: Neutrophil-activating peptide-2 and melanoma growth-stimulatory activity are functional as monomers for neutrophil activation. *J Biol Chem* 272:1725-1729 (1997).
- Schadendorf D, Kern MA, Artuc M, Pahl HL, Rosenbach T, Fichtner I, Nurnberg W, Stuting S, vonStebut E, Worm M, Makki A, Jurgovsky K, Kolde G, Henz BM: Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptosis via activation of AP-1 *in vitro*, and causes growth inhibition in xenografts *in vivo*. *J Cell Biol* 135:1889-1898 (1996).
- Schaidler H, Rech-Weichselbraun I, Richtig E, Seidl H, Soyer HP, Smolle J, Kerl H: Circulating adhesion molecules as prognostic factors for cutaneous melanoma. *J Am Acad Dermatol* 36:209-213 (1997).
- Schioth HB, Muceniece R, Larsson M, Mutulis F, Szardenings M, Prusis P, Lindeberg G, Wikberg JES: Binding of cyclic and linear MSH core peptides to the melanocortin receptor subtypes. *Eur J Pharmacol* 319:369-373 (1997).
- Schioth HB, Muceniece R, Szardenings M, Prusis P, Lindeberg G, Sharma SD, Hrubby VJ, Wikberg JES: Characterisation of D117A and H260A mutations in the melanocortin 1 receptor. *Mol Cell Endocrinol* 126:213-219 (1997).
- Schioth HB, Muceniece R, Szardenings M, Prusis P, Wikberg JES: Evidence indicating that the TM4, EL2, and TM5 of the melanocortin 3 receptor do not participate in ligand binding. *Biochem Biophys Res Commun* 229:687-692 (1996).
- Seiberg M, Wisniewski S, Cauwenbergh G, Shapiro SS: Trypsin-induced follicular papilla apoptosis results in delayed hair growth and pigmentation. *Develop Dynam* 208:553-564 (1997).
- Siwek B, DePauw-Gillet MC, Quetin-Leclercq J, Angenot L, Bassleer R: Characterization of non pigmented B16 melanoma cell-derived cytotoxic factors. *Chem Biol Interact* 103:59-73 (1997).
- Takayama H, LaRochelle WJ, Sharp R, Otsuka T, Kriebel P, Anver M, Aaronson SA, Merlino G: Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. *Proc Natl Acad Sci USA* 94:701-706 (1997).
- Thomas CP, Buronfosse A, Portoukalian J, Fertil B: The gangliosides as a possible molecular coupling factor between the proportion of radiosensitive cells *in vitro* and the metastatic potential *in vivo* within a human melanoma cell line. *Br J Cancer* 75:639-649 (1997).

- Tillet Y, Batailler M, Fellmann D: Distribution of melanin-concentrating hormone (MCH)-like immunoreactivity in neurons of the diencephalon of sheep. *J Chem Neuroanat* 12:135-145 (1996).
- Whiteman DC, Valery P, McWhirter W, Green AC: Risk factors for childhood melanoma in Queensland, Australia. *Int J Cancer* 70:26-31 (1997).
- Wilkinson GS: Are low radiation doses or occupational exposures really risk factors for malignant melanoma? Commentary. *Am J Epidemiol* 145:532-535 (1997).
- Yang D, Hayashi H, Takii T, Mizutani Y, Inukai Y, Onozaki K: Interleukin-1-induced growth inhibition of human melanoma cells -Interleukin-1-induced antizyme expression is responsible for ornithine decarboxylase activity down-regulation. *J Biol Chem* 272:3376-3383 (1997).
- ❖ Yang YK, Ollmann MM, Wilson BD, Dickinson C, Yamada T, Barsh GS, Gantz I: Effects of recombinant agouti-signaling protein on melanocortin action. *Mol Endocrinol* 11:274-280 (1997).
- Zheng T, Villalobos C, Nusser KD, Gettys TW, Faught WJ, Castano JP, Frawley LS: Phenotypic characterization and functional correlation of  $\alpha$ -MSH binding to pituitary cells. *Amer J Physiol Endocrinol Met* 35:E282-E287 (1997).

## TYROSINASE, TYROSINASE RELATED PROTEINS & MOLECULAR BIOLOGY

- Cooksey CJ, Land EJ, Ramsden CA, Riley PA: Tyrosinase-mediated cytotoxicity of 4-substituted phenols: Quantitative structure-thiol-reactivity relationships of the derived o-quinones (Vol 10, pg 119, 1995). *Anti Cancer Drug Des* 11:637(1996).
- Cooksey CJ, Land EJ, Rushton FAP, Ramsden CA, Riley PA: Tyrosinase-mediated cytotoxicity of 4-substituted phenols: Use of QSAR to forecast reactivities of thiols towards the derived ortho-quinones. *Quant Struct Act Relat* 15:498-503 (1996).
- Dhar MS, Johnson DK: A microsatellite map of the pink-eyed dilution (p) deletion complex in mouse Chromosome 7. *Mamm Genome* 8:143-145 (1997).
- Fan W, Boston BA, Kesterson RA, Hruby VJ, Cone RD: Role of melanocortineric neurons in feeding and the agouti obesity syndrome. *Nature* 385:165-168 (1997).
- Glaser R, Hauschild A, Lohmeier C, Christophers E: Detection of circulating malignant melanoma cells by tyrosinase PCR: Fact or fancy? *Head and Neck Cancer - Advances in Basic Research* 1114 665-670:-670 (1996).
- Jeffery G, Brem G, Montoliu L: Correction of retinal abnormalities found in albinism by introduction of a functional tyrosinase gene in transgenic mice and rabbits. *Dev Brain Res* 99:95-102 (1997).
- ❖ Kondoh H, Wilczek A, Narimizu S, Mishima Y: Mouse fibroblast expressing human tyrosinase with DHICA-oxidase activity produces predominantly pheomelanin deposit in lysosome. *Zool Sci* 13:825-831 (1996).
- ❖ Li PX, Cheng L, Wen DR, Wissmann PB, Cheng J, Grody WW, Cochran AJ: Demonstration of cytoplasmic tyrosinase mRNA in tissue-cultured cells by reverse transcription (RT) *in situ* polymerase chain reaction (PCR) and RT PCR *in situ* hybridization. *Diagn Mol Pathol* 6:26-33 (1997).
- Mynatt RL, Miltenberger RJ, Klebig ML, Zemel MB, Wilkinson JE, Wilkison WO, Woychik RP: Combined effects of insulin treatment and adipose tissue-specific agouti expression on the development of obesity. *Proc Natl Acad Sci USA* 94:919-922 (1997).
- Popper P, Farber DB, Micevych PE, Minoofar K, Bronstein JM: TRPM-2 expression and tunel staining in neurodegenerative diseases: Studies in wobbler and rd mice. *Exp Neurol* 143:246-254 (1997).
- Riley PA, Cooksey CJ, Johnson CI, Land EJ, Latter AM, Ramsden CA: Melanogenesis-targeted anti-melanoma pro-drug development: Effect of side-chain variations on the cytotoxicity of tyrosinase-generated ortho-quinones in a model screening system. *Eur J Cancer* 33:135-143 (1997).
- Sato S, Masuya H, Numakunai T, Satoh N, Ikeo K, Gojobori T, Tamura K, Ide H, Takeuchi T, Yamamoto H: Ascidian tyrosinase gene: Its unique structure and expression in the developing brain. *Develop Dynam* 208:363-374 (1997).
- Shimizu H: Technical advances in prenatal diagnosis of tyrosinase-negative oculocutaneous albinism. *Acta Derm Venereol [Stockh]* 77:10-13 (1997).
- Shutter JR, Graham M, Kinsey AC, Scully S, Luthy R, Stark KL: Hypothalamic expression of *ART*, a novel gene related to agouti, is up-regulated in obese and diabetic mutant mice. *Gene Develop* 11:593-602 (1997).
- Siegrist W, Drozd R, Cotti R, Willard DH, Wilkison WO, Eberle AN: Interactions of  $\alpha$ -melanotropin and agouti on B16 melanoma cells: Evidence for inverse agonism of agouti. *J Recept Signal Transduct Res* 17:75-98 (1997).
- Stevens G, Ramsay M, Jenkins T: Oculocutaneous albinism (OCA2) in sub-Saharan Africa: Distribution of the common 2.7-kb P gene deletion mutation. *Hum Genet* 99:523-527 (1997).
- ❖ Vage DI, Lu DS, Klungland H, Lien S, Adalsteinsson S, Cone RD: A non-epistatic interaction of agouti and extension in the fox, *Vulpes vulpes*. *Nat Genet* 15:311-315 (1997).
- Wu M, Rinchik EM, Wilkinson E, Johnson DK: Inherited somatic mosaicism caused by an intracisternal A particle insertion in the mouse tyrosinase gene. *Proc Natl Acad Sci USA* 94:890-894 (1997).
- Xu YM, Stokes AH, Freeman WM, Kumer SC, Vogt BA, Vrana KE: Tyrosinase mRNA is expressed in human substantia nigra. *Mol Brain Res* 45:159-162 (1997).

## MISCELLANEOUS

Binder M, PuespoeckSchwarz M, Steiner A, Kittler H, Muellner M, Wolff K, Pehamberger H: Epiluminescence microscopy of small pigmented skin lesions: Short-term formal training improves the diagnostic performance of dermatologists. *J Am Acad Dermatol* 36:197-202 (1997).

Goda M, Fujii R: Biology of the chromatophores of the Ice Goby, *Leucopsarion petersii*. *Zool Sci* 13:783-793 (1996).

Gygi SP, Wilkins DG, Rollins DE: A comparison of phenobarbital and codeine incorporation into pigmented and nonpigmented rat hair. *J Pharm Sci* 86:209-214 (1997).

Hanrahan PF, Hersey P, Menzies SW, Watson AB, DEste CA: Examination of the ability of people to identify early changes of melanoma in computer-altered pigmented skin lesions. *Arch Dermatol* 133:301-311 (1997).

Kelsh RN, Brand M, Jiang YJ, Heisenberg CP, Lin S, Haffter P, Odenthal J, Mullins MC, vanEeden FJM, FurutaniSeiki M, Granato M, Hammerschmidt M, Kane DA, Warga RM, Beuchle D, Vogelsang L, NussleinVolhard C: Zebrafish pigmentation mutations and the processes of neural crest development. *Development* 123:369-389:369-389 (1996).

Kim RY, Hu LK, Foster BS, Gragoudas ES, Young LHY: Photodynamic therapy of pigmented choroidal melanomas of greater than 3-mm thickness. *Ophthalmology* 103:2029-2036 (1996).

LeNet JL, Orth G, Sundberg JP, Cassonnet P, Poisson L, Masson MT, George C, Longeart L: Multiple pigmented cutaneous papules associated with a novel canine papillomavirus in an immunosuppressed dog. *Vet Pathol* 34:8-14 (1997).

Michailov N, Peeva M, Angelov I, Wohrle D, Muller S, Jori G, Ricchelli F, Shopova M: Fluence rate effects on photodynamic therapy of B16 pigmented melanoma. *J Photochem Photobiol B Biol* 37:154-157 (1997).

Mitchell CH, Zhang JJ, Wang LW, Jacob TJC: Volume-sensitive chloride current in pigmented ciliary epithelial cells: Role of phospholipases. *Amer J Physiol Cell Physiol* 41:C212-C222 (1997).

Mitchell DL: Survival of the most pigmented. *Photochem Photobiol* 65:R3-R4 (1997).

Rehnstrom AL, Free SJ: The isolation and characterization of melanin-deficient mutants of *Monilia fruticola*. *Physiol Molec Plant Pathol* 49:321-330 (1996).

Tong YY, Lighthart B: Solar radiation is shown to select for pigmented bacteria in the ambient outdoor atmosphere. *Photochem Photobiol* 65:103-106 (1997).

### Demographics of the PASPCR

Degree	Type of Member	North America	South / Central America	Europe	Japan	Other	Total
<b>Predoctoral</b>	<b>Commercial</b>	2	0	0	2	0	4
	<b>Institutional</b>	18	0	0	0	0	18
<b>PhD or DVM</b>	<b>Commercial</b>	14	0	1	1	0	16
	<b>Institutional</b>	66	4	0	2	2	74
<b>MD</b>	<b>Commercial</b>	0	0	0	0	0	0
	<b>Institutional</b>	24	0	4	1	2	31
<b>MD and PhD</b>	<b>Commercial</b>	0	0	0	0	0	0
	<b>Institutional</b>	16	0	0	2	4	22
<b>Totals</b>		139	4	5	8	8	165
	<b>Commercial</b>	20	12 %				
	<b>Institutional</b>	145	88 %				
	<b>Male</b>	123	75 %				
	<b>Female</b>	42	25 %				